<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2935</article-id>
         <article-id pub-id-type="publisher-id">2935</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Neurobiology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Nevrobiologija</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Pregledni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Nevrobiologija</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Nuklearnomedicinske preiskave pri diagnosticiranju demence in parkinsonizmov</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Nuclear Medicine Investigations in Dementia and Parkinsonism</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Nuklearnomedicinske preiskave pri diagnosticiranju demence in parkinsonizmov</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Rus</surname>
                  <given-names>Tomaž</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Jamšek</surname>
                  <given-names>Jan</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Berlot</surname>
                  <given-names>Rok</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Šurlan Popovič</surname>
                  <given-names>Katarina</given-names>
               </name>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Grmek</surname>
                  <given-names>Marko</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Trošt</surname>
                  <given-names>Maja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff2">2</xref>
               <xref ref-type="aff" rid="aff4">4</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za bolezni živčevja, Nevrološka klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Vascular Neurology and Intensive Therapy, Division of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Klinika za nuklearno medicino, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff3">
            <aff xml:lang="sl">
               <label>3</label>
               <institution>Klinični inštitut za radiologijo, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>3</label>
               <institution>Institute of Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff4">
            <aff xml:lang="sl">
               <label>4</label>
               <institution>Katedra za nevrologijo, Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>4</label>
               <institution>Department of Neurology, Faculty of medicine, University of Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Tomaž Rus, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>4</month>
            <year>2020</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>4</month>
            <year>2020</year>
         </pub-date>
         <volume>89</volume>
         <issue>3–4</issue>
         <fpage>203</fpage>
         <lpage>22</lpage>
         <history>
            <date date-type="received">
               <day>15</day>
               <month>3</month>
               <year>2019</year>
            </date>
            <date date-type="accepted">
               <day>6</day>
               <month>9</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2020, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2020, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2020</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Nevrodegenerativne bolezni možganov, ki se klinično izrazijo kot demenca ali parkinsonizem, postajajo s staranjem prebivalstva vse pogostejše. Zgodnja in pravilna postavitev diagnoze je pomembna zaradi izključevanja ozdravljivih vzrokov, ustreznega simptomatskega zdravljenja, socialnih ukrepov in vključevanja bolnikov v klinične raziskave. Povsem dokončno diagnozo večine nevrodegenerativnih bolezni možganov lahko postavimo le na podlagi patohistološkega vzorca možganovine. Za živa pa so nam v veliko pomoč funkcijske nuklearnomedicinske preiskave, s katerimi lahko prikažemo spremenjeno področno presnovo možganov, motnje na ravni nevrotransmitrskih sistemov in patomorfološki substrat bolezni – tj. kopičenje patoloških beljakovin. Glede na značilne spremembe regionalne presnove možganov, ki jih preučujemo s pozitronsko emisijsko tomografijo (PET) možganov z radioaktivnim fluorom (<sup>18</sup>F) označene deoksiglukoze, lahko razlikujemo med Alzheimerjevo boleznijo, demenco z Lewyjevimi telesci, frontotemporalno demenco in redkejšimi vzroki kognitivnega upada ter med Parkinsonovo boleznijo in drugimi nevrodegenerativnimi parkinsonizmi. Z ugotavljanjem integritete dopaminergičnega sistema (npr. scintigrafijo dopaminskega prenašalca, DaTSCAN) lahko razlikujemo med nevrodegenerativnimi parkinsonizmi in drugimi možnimi vzroki težav. Amiloidni PET možganov nam prikaže prisotnost in značilno razporeditev čezmernega kopičenja amiloida pri bolnikih z Alzheimerjevo boleznijo že pred pojavom kliničnih znakov bolezni. V prispevku predstavljamo nuklearnomedicinske preiskave, obravnavamo indikacije in značilne spremembe ter omejitve teh preiskav pri diagnosticiranju nevrodegenerativnih bolezni možganov.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>The incidence of neurodegenerative brain disorders presenting as dementia or parkinsonism is increasing with population aging. Early and correct diagnosis is essential for the exclusion of potentially curable causes, to optimize symptomatic treatment, social care and to select patients for clinical trials. Final diagnosis of most neurodegenerative brain diseases can only be made by histopathological examination of the brain tissue. However, functional nuclear-medicine investigations contribute greatly to the diagnosis <italic>in vivo</italic>. Changes in regional brain metabolism, neurotransmitter system dysfunction and misfolded protein deposition can be observed. Based on specific changes in regional brain metabolism measured with <sup>18</sup>F-FDG PET, we can distinguish between Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and between Parkinson’s disease and other neurodegenerative parkinsonisms. Dopaminergic system imaging (e.g. dopamine transporter scintigraphy, DaTSCAN) enables us to discriminate neurodegenerative parkinsonism from alternative causes. Excessive deposition of amyloid-β, a pathological hallmark of Alzheimer’s disease, can be identified by amyloid PET already in preclinical subjects. Nuclear medicine imaging methods, indications, characteristic findings and limitations of these investigations in neurodegenerative brain disorders are presented in this article.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>metabolizem možganov</kwd>
            <kwd>scintigrafija dopaminskega prenašalca</kwd>
            <kwd>18F-FDG PET možganov</kwd>
            <kwd>amiloidni PET možganov</kwd>
            <kwd>nevrodegenerativne bolezni</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>brain metabolism</kwd>
            <kwd>dopamine transporter scintigraphy</kwd>
            <kwd>brain 18F-FDG PET</kwd>
            <kwd>brain amyloid PET</kwd>
            <kwd>neurodegenerative disorders</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Bolezenske procese živčevja, za katere je značilno napredujoče propadanje nevronov, poimenujemo s skupnim izrazom nevrodegenerativne bolezni. Klinično se nevrodegenerativne bolezni možganov najpogosteje izrazijo s kognitivnim upadom in/ali z motnjami gibanja (<xref ref-type="bibr" rid="b1">1</xref>). Njihov skupni patogenetski mehanizem je kopičenje patoloških beljakovin v živčevju, ki poškodujejo nevrone in njihove povezave (<xref ref-type="bibr" rid="b2">2</xref>).</p>
         <p>Dokončno diagnozo nevrodegenerativnih parkinsonizmov lahko postavimo na podlagi patohistološkega pregleda vzorca možganovine po bolnikovi smrti. Za živa pa diagnoza sicer temelji na klinični sliki, pomagamo pa si lahko z izvidi slikovnih preiskav. Pri diagnosticiranju demenc se vse bolj uveljavljajo biološki označevalci, s pomočjo katerih lahko že za živa dokažemo patološke procese v možganih. Tako poznamo označevalce nevrodegeneracije, kopičenja patoloških beljakovin – amiloida beta in beljakovine tau (<xref ref-type="bibr" rid="b3">3</xref>).</p>
         <p>Pravilna in zgodnja klinična diagnoza je pomembna, saj so od nje odvisni izbira zdravljenja, napoved izida, dolgoročni načrti bolnika in svojcev in nenazadnje izbor ustreznih bolnikov za raziskave, kar lahko pomembno prispeva k uspehu kliničnih raziskav (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b5">5</xref>). Poleg kliničnega nevrološkega in nevropsihološkega pregleda, laboratorijskih preiskav krvi in likvorja, strukturnega slikanja in v nekaterih primerih nevrofizioloških preiskav pri postavitvi diagnoze pomagajo tudi funkcijske slikovne metode. S pozitronsko emisijsko tomografijo (PET) uporabo fluorodeoksiglukoze, označene z radioaktivnim fluorom (<sup>18</sup>F-FDG), lahko preučujemo presnovo oziroma sinaptično aktivnost možganov in s tem dokažemo morebitno nevrodegeneriranost v možganih. Druge funkcijske slikovne preiskave lahko prikažejo integriteto nevrotransmitrskih sistemov (npr. scintigrafija dopaminskega prenašalca ali dopaminskih receptorjev) ali pa kopičenje patoloških proteinov (npr. amiloida beta in beljakovine tau) (<xref ref-type="bibr" rid="b6">6</xref>). Možgansko aktivnost lahko posredno preko sprememb možganskega pretoka preučujemo tudi s funkcijskim magnetnoresonančnim slikanjem (MRI) ali s perfuzijsko scintigrafijo.</p>
         <p>Prispevek vsebuje pregled slikovnih metod, predvsem nuklearnomedicinskih funkcijskih preiskav, ki jih uporabljamo pri diagnosticiranju nevrodegenerativnih bolezni možganov, ki jih na podlagi prevladujočih simptomov delimo v dve skupini: demenca in parkinsonizmi (<xref ref-type="bibr" rid="b1">1</xref>).</p>
         <sec id="s1.1" sec-type="18F-FDG PET možganov">
            <label>1.1</label>
            <title><sup>18</sup>F-FDG PET možganov</title>
            <p>Preiskava PET možganov s <sup>18</sup>F-FDG (<sup>18</sup>F-FDG PET) je nuklearnomedicinska slikovna metoda, ki se v klinični praksi najpogosteje uporablja pri diagnosticiranju onkoloških, vnetnih in infekcijskih ter kardioloških bolezni (<xref ref-type="bibr" rid="b7">7</xref>), v zadnjem desetletju pa je postala zlati standard tudi pri diagnosticiranju nevrodegenerativnih bolezni možganov (<xref ref-type="bibr" rid="b8">8</xref>-<xref ref-type="bibr" rid="b10">10</xref>).</p>
            <p>Radiofarmak <sup>18</sup>F-FDG je strukturni analog glukoze, ki je glavni energijski substrat možganskih celic. Kopičenje <sup>18</sup>F-FDG v možganih je posledica visokega privzema glukoze v nevronih in astrocitih. Po privzemu v možganske celice se <sup>18</sup>F-FDG fosforilira z encimom heksokinaze. <sup>18</sup>F-glukoza-6-fosfat se dalje ne presnavlja in ostane ujet v celicah, kar nam omogoča prikaz presnovne aktivnosti možganovine z uporabo PET. Privzem <sup>18</sup>F-FDG v možganovini je tesno povezan z nevronsko sinaptično aktivnostjo zlasti v področju sive možganovine in bazalnih ganglijev ter predstavlja presnovno aktivnost možganov (<xref ref-type="bibr" rid="b11">11</xref>). Pri bolnikih z nevrodegenerativnimi boleznimi se funkcijske spremembe na <sup>18</sup>F-FDG PET možganov navadno pojavijo več let pred vidnimi znaki atrofije pri strukturnem slikanju možganov z računalniško tomografijo (CT) in MRI tomografijo (<xref ref-type="bibr" rid="b12">12</xref>).</p>
            <p>
               <sup>18</sup>F-FDG PET možganov v klinični praksi uporabljamo pri diagnosticiranju demenc oziroma kognitivnih motenj (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b10">10</xref>) in parkinsonizmov (<xref ref-type="bibr" rid="b9">9</xref>), pri katerih lahko razločimo številne za določen sindrom specifične vzorce kopičenja <sup>18</sup>F-FDG, povezane s klinično sliko. Vloga CT pri <sup>18</sup>F-FDG PET je pomembna zlasti za korigiranje atenuacije PET-slik, hkrati pa nam omogoča anatomsko koregistracijo; v ta namen uporabljamo t. i. lokalizacijski ali nizkodozni CT. Vse sodobne PET/CT naprave omogočajo tudi zajem CT slik v diagnostični kakovosti, čeprav je glavni namen <sup>18</sup>F-FDG PET preiskave opredelitev delovanja posameznih področij možganov. Vloga diagnostičnega CT pri teh boleznih pa se omejuje predvsem za izključitev drugih bolezenskih stanj (npr. možganskih tumorjev).</p>
            <p>
               <sup>18</sup>F-FDG PET možganov v Sloveniji izvajamo v skladu s smernicami Evropskega združenja za nuklearno medicino (<italic>angl.</italic> European Association of Nuclear Medicine, EANM) (<xref ref-type="bibr" rid="b13">13</xref>). Bolniki morajo biti pred preiskavo obvezno vsaj štiri ure tešči, morajo biti zmožni sodelovanja (tj. mirno ležati vsaj 45 min) in ne smejo imeti hude klavstrofobije.</p>
            <p>Za optimalno izvedbo preiskave je ključno, da je raven krvnega sladkorja (KS) pred vnosom <sup>18</sup>F-FDG ustrezno urejena. Naš center je mejo določil &lt; 10 mmol/l, smernice pa priporočajo mejo KS &lt; 160 mg/dl, kar znaša približno 9 mmol/l (<xref ref-type="bibr" rid="b13">13</xref>). Visoka raven KS namreč zmanjša privzem <sup>18</sup>F-FDG v možganovini, zaradi česar so lahko končne PET slike slabše kakovosti za diagnostične namene. Pri ravni KS &gt; 10 mmol/l se preiskava lahko izvede ob ustrezni pripravi bolnika s kratko delujočim inzulinom.</p>
            <p>Po intravenskem vnosu radiofarmaka morajo bolniki 30 minut mirno ležati v zatemnjenem prostoru z odprtimi očmi (<xref ref-type="bibr" rid="b13">13</xref>), čemur sledi slikanje, ki traja 10–15 min. Za optimalni izvid preiskave je priporočljivo, da ga skupaj pripravita specialist nuklearne medicine in nevrolog.</p>
         </sec>
         <sec id="s1.2"
              sec-type="Slikovni prikaz integritete dopaminergičnega sistema">
            <label>1.2</label>
            <title>Slikovni prikaz integritete dopaminergičnega sistema</title>
            <p>Poleg sprememb presnove možganov lahko pri nevrodegenerativnih boleznih z nuklearnomedicinskimi slikovnimi metodami ugotavljamo tudi integriteto dopaminergičnega sistema. Pri parkinsonizmih propadajo dopaminergični nevroni v substanci nigri, katerih živčni končiči projicirajo v striatum. Upad dopaminergičnih nevronov in s tem povezano predsinaptično okvaro dopaminergičnega sistema lahko za živa<italic> </italic>prikažemo z radiofarmaki, ki se vežejo na presinaptične nevrone v striatumu oz. jih ti selektivno privzemajo (<xref ref-type="bibr" rid="b14">14</xref>). Z radiofarmakom <sup>18</sup>F-fluorodopa prikažemo aktivnost dopa-dekarboksilaze ter zmožnost shranjevanja dopamina v presinaptičnih nevronih (<xref ref-type="bibr" rid="b14">14</xref>). Podoben podatek o stanju presinaptičnega dopaminergičnega sistema dobimo pri uporabi radiofarmakov, ki se selektivno vežejo na dopaminski prenašalec na predsinaptičnih nevronih (membranski kanalček, ki skrbi za ponovni privzem dopamina iz sinapse; (<italic>angl.</italic> dopamin transporter, DAT). V klinične namene sta Evropska agencija za zdravila (EMA) in ameriški Zvezni urad za hrano in zdravila (FDA) odobrila radiofarmak <sup>123</sup>I-ioflupan (<sup>123</sup>I-β-CIT-FP) – lastniško ime DaTSCAN, ki ga rutinsko uporabljamo tudi v Sloveniji. Tretja tarčna beljakovina, s katero lahko preučujemo gostoto presinaptičnih nevronov, je vezikularni monoaminski prenašalec tipa 2 (VMAT2), proteinski kompleks na membrani nevrotransmiterskih veziklov, ki sodeluje pri prenosu monoaminskih živčnih prenašalcev, tudi dopamina (<xref ref-type="bibr" rid="b15">15</xref>).</p>
            <p>V raziskovalne namene lahko preučujemo tudi integriteto postsinaptičnih dopaminergičnih nevronov v bazalnih ganglijih z radiofarmaki, ki se vežejo na dopaminski receptor D2: <sup>11</sup>C-racloprid in <sup>123</sup>I-iodobenzamide (IBZM) (<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b16">16</xref>). Čeprav lahko na osnovi te preiskave do določene mere ločimo med Parkinsonovo boleznijo (PB) in drugimi nevrodegenerativnimi parkinsonizmi, pa ima to slikanje dosti manjšo moč razlikovanja kot <sup>18</sup>F-FDG PET možganov (<xref ref-type="bibr" rid="b17">17</xref>) in se za namen razlikovanja med parkinsonizmi ne uporablja.</p>
         </sec>
         <sec id="s1.3" sec-type="Slikovni prikaz patoloških proteinov v možganih">
            <label>1.3</label>
            <title>Slikovni prikaz patoloških proteinov v možganih</title>
            <p>Za nevrodegenerativne bolezni je značilno odlaganje različnih patoloških proteinov na specifičnih mestih v možganih. V patofiziološki proces so najpogosteje vključeni amiloid beta, tau in alfa-sinuklein (α-syn). Amiloid beta se v možganih odlaga pri cerebralni amiloidni angiopatiji ter skupaj z beljakovino tau pri Alzheimerjevi bolezni (AB). Med tauopatije, oziroma bolezni, pri katerih se čezmerno kopiči protein tau, uvrščamo frontotemporalno demenco (FTD), kortikobazalno degeneracijo (KBD) in progresivno supranuklearno paralizo (PSP) (slednji bolezni klinično uvrščamo med t. i. parkinsonizme plus). V možganovini se odlaga α-syn pri PB, demenci z Lewyjevimi telesci (DLT) ter pri multipli sistemski atrofiji (MSA) (<xref ref-type="bibr" rid="b2">2</xref>). Kopičenje določenega proteina torej ni značilno le za eno bolezen oziroma sindrom, temveč se lahko patološki proteini kopičijo v raznovrstnih kombinacijah pri različnih nevrodegenarativnih sindromih. Tako lahko govorimo o kontinuumu proteinopatij z različnimi kliničnimi slikami (<xref ref-type="fig" rid="fig1">Slika 1</xref>) (<xref ref-type="bibr" rid="b18">18</xref>).</p>
            <fig position="anchor" id="fig1">
               <label>Slika 1:</label>
               <caption>
                  <p> Genetski, patološki in klinični kontinuum nevrodegenerativnih bolezni – proteinopatij. Prikazane so bolezni, ki jih povezujemo s posameznimi proteini, patološkimi substrati in geni, ki posredno ali neposredno vplivajo na odlaganje posameznega proteina v možganovini. Razvidno je prekrivanje proteinopatij pri različnih kliničnih sindromih. ALS – amiotrofična lateralna skleroza. FTD BMN – frontotemporalna demenca z boleznijo motoričnega nevrona, srPPA - semantična različica primarne progresivne afazije, vFTD – vedenjska različica frontotemporalne demence, nfrPPA – nefluentna različica primarne progresivne afazije, KBS – kortikobazalni sindrom, PSP – progresivna supranuklearna paraliza, lrPPA – logopenična različica primarne progresivne afazije, AB – Alzheimerjeva bolezen, DLT – demenca z Lewyjevimi telesci, PBD – parkinsonova bolezen z demenco, PB – Parkinsonova bolezen, CJB – Creutzfeldt-Jakobova bolezen, GSS - Gerstmann–Sträussler–Scheinkerjev sindrom, NFP – nevrofibrilarne pentlje. Prirejeno po Villemagne, 2015 (<xref ref-type="bibr" rid="b18">18</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-01.png"/>
               </p>
            </fig>
            <p>Do nedavnega je bil neposreden dokaz odlaganja posamezne beljakovine možen le s patohistološkim pregledom vzorca možganovine z imunohistokemijskimi metodami. Na podlagi teh metod je več skupin razvilo radiofarmake, ki se za živa<italic> </italic>vežejo na patološke beljakovine. Prvi radiofarmak, ki se specifično veže na amiloid-beta, so razvili na prelomu tisočletja, t. i. <italic>Pittsburgh compound B</italic> (<sup>11</sup>C-PiB) (<xref ref-type="bibr" rid="b19">19</xref>). <sup>11</sup>C-PiB se zaradi tehničnih omejitev (označen je s kratkoživim radioaktivnim elementom <sup>11</sup>C) lahko uporablja le v ustanovah, ki imajo ciklotron v neposredni bližini. V zadnjih letih sta EMA in ameriški FDA za klinično uporabo odobrila uporabo treh radiofarmakov, označenih z <sup>18</sup>F, ki se vežejo na amiloid beta: <sup>18</sup>F-flutemetamol, <sup>18</sup>F-florbetaben in <sup>18</sup>F-florbetapir (<xref ref-type="bibr" rid="b20">20</xref>-<xref ref-type="bibr" rid="b22">22</xref>). Uporaba radiofarmakov, označena s <sup>18</sup>F, ki ima daljšo razpolovno dobo (110 minut) in se zato lahko prevaža v ustanove, ki so do nekaj 100 km oddaljene od ciklotrona, je omogočila prehod amiloidnega slikanja v klinično prakso.</p>
            <p>Razvoj radiofarmakov, ki se vežejo na beljakovino tau, je kompleksnejši, saj se le-ta nahaja znotraj živčnih celic in obstaja v šestih izoformah. Tau se na različne načine posttranslacijsko modificira. Odlaga se v različnih fibrilnih oblikah, v različnih celicah in predelih možganov (<xref ref-type="bibr" rid="b23">23</xref>). V raziskovalne namene se uporablja več molekul (najpogostejše so <sup>18</sup>F-AV1451, <sup>18</sup>F-THK5317, <sup>18</sup>FTHK5351 in <sup>11</sup>C-PBB3 (<xref ref-type="bibr" rid="b6">6</xref>)), najbolj raziskana je uporaba pri diagnosticiranju AB, nekoliko manj pa pri diagnosticiranju drugih tauopatij (KBD, PSP, FTLD-17) (<xref ref-type="bibr" rid="b23">23</xref>).</p>
            <p>Razvoj radiofarmakov z vezavo na α-syn (PB, MSA, DLB) še poteka. Težava je predvsem v specifičnosti radiofarmaka ter farmakokinetskih lastnostih doslej uporabljenih molekul. Poleg tega je koncentracija α-syn v možganovini pri alfasinukleinopatijah, tj. boleznih, pri katerih prihaja do čezmernega kopičenja α-syn, sorazmerno nizka, kar lahko predstavlja težavo pri zajemanju PET slik (<xref ref-type="bibr" rid="b24">24</xref>).</p>
         </sec>
         <sec id="s1.4" sec-type="Odčitavanje nuklearnomedicinskih preiskav možganov">
            <label>1.4</label>
            <title>Odčitavanje nuklearnomedicinskih preiskav možganov</title>
            <p>Pri ocenjevanju <sup>18</sup>F-FDG PET možganov v kliničnodiagnostične namene sodelujeta specialista nuklearne medicine in nevrologije. Po vidni (kvalitativni) oceni slike si pomagamo tudi s statističnimi metodami za analizo slike. Slike posameznika ali skupine bolnikov primerjamo z zdravimi preiskovanci oz. z drugo skupino bolnikov. Predpogoj za primerjavo je prostorska normalizacija, pri kateri sliko posameznika prostorsko prilagodimo splošnemu vzorcu. Z univariatnimi metodami, med katerimi se najpogosteje uporablja statistična parametrična kartografija (<italic>angl.</italic> Statistical Parametric Mapping, SPM (<xref ref-type="bibr" rid="b25">25</xref>)) primerjamo posamezne »voksle« obeh skupin preiskovancev in rezultat predstavimo v obliki normaliziranih t- oz. z-kart (<xref ref-type="fig" rid="fig2">Slika 2</xref>a). Prostorska razporeditev sprememb je še bolj povedna, če tako pridobljeni rezultat stereotaktično projiciramo na možgansko skorjo, kar nam omogoča npr. program 3D-SPP Neurostat (<italic>angl.</italic> Three-dimensional Stereotactic Surface Projections<italic> </italic>(<xref ref-type="bibr" rid="b26">26</xref>). Glej <xref ref-type="fig" rid="fig2">Sliko 2</xref>b). Podobne programe za statistično obdelavo slik vsebujejo tudi paketi programske opreme, ki jih zagotavljajo proizvajalci kamer gama in PET (npr. Scenium, Siemens Molecular Imaging Ltd.).</p>
            <fig position="anchor" id="fig2">
               <label>Slika 2:</label>
               <caption>
                  <p> Prikaz razlik med bolniki z Alzheimerjevo boleznijo in zdravimi preiskovanci s statističnimi metodami. A – univariatna analiza z uporabo statistične parametrične kartografije (<italic>angl. </italic>Statistic parametric mapping, SPM; verzija SPM12, primerjava med 48 bolniki z AB in 40 zdravimi preiskovanci, modra področja pomenijo sorazmerno znižano, rdeča pa sorazmerno povišano presnovno aktivnost možganovine, p = 0,001) (vir: Klinika za nuklearno medicino, UKC Ljubljana), B – stereotaktična projekcija statističnih razlik v presnovi možganov med bolnikom z AB in skupino zdravih preiskovancev na možgansko skorjo (3D-SPP Neurostat); predstavljena so le področja s sorazmerno znižano presnovno aktivnostjo (vir: Klinika za nuklearno medicino, UKC Ljubljana).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-02.png"/>
               </p>
            </fig>
            <p>Z naprednejšimi multivariatnimi metodami analize <sup>18</sup>F-FDG PET možganov lahko prepoznamo za sindrom specifične presnovne vzorce funkcijsko povezanih predelov možganov. Ena od tovrstnih metod je multivariatna mrežna analiza, ki temelji na analizi osnovnih komponent (<italic>angl.</italic> scaled subprofile mapping – principal component analysis, SSM-PCA) (<xref ref-type="bibr" rid="b27">27</xref>). Glej <xref ref-type="fig" rid="fig8">Sliko 8</xref>). Ta metoda je namenjena identificiranju vzorcev in tudi prospektivnemu spremljanju izraženosti presnovnih vzorcev pri posameznih preiskovancih (<xref ref-type="bibr" rid="b28">28</xref>).</p>
         </sec>
      </sec>
      <sec id="s2"
           sec-type="Vloga nuklearnomedicinskih preiskav pri diagnosticiranju demenc 18F-FDG PET možganov">
         <label>2</label>
         <title>Vloga nuklearnomedicinskih preiskav pri diagnosticiranju demenc <sup>18</sup>F-FDG PET možganov</title>
         <sec id="s2.1" sec-type="Alzheimerjeva bolezen">
            <label>2.1</label>
            <title>Alzheimerjeva bolezen</title>
            <p>AB je najpogostejša nevrodegenerativna bolezen možganov in najpogostejši vzrok za demenco. Večinoma zbolijo starejši od 65 let (<xref ref-type="bibr" rid="b1">1</xref>). Število obolelih v Sloveniji ocenjujejo na okoli 25.000 ljudi (<xref ref-type="bibr" rid="b29">29</xref>). Klinično je za bolezen značilen napredujoč kognitivni upad, ki se na začetku kaže z motnjo kratkoročnega spomina in vidno-prostorske orientacije, postopno pa opešajo vse kognitivne funkcije, kar privede do invalidnosti. To povzroči veliko breme za svojce, zdravstveni sistem in družbo nasploh. Bolezenski procesi se v možganih prično desetletja pred pojavom demence.</p>
            <p>Povzetek tipičnih sprememb možganske presnove pri AB na <sup>18</sup>F-FDG PET možganov predstavljata <xref ref-type="table" rid="table1">Tabela 1</xref> in <xref ref-type="fig" rid="fig3">Slika 3</xref>B (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b30">30</xref>).</p>
            <table-wrap position="anchor" id="table1">
               <label>Tabela 1:</label>
               <caption>
                  <p> Presnovne značilnosti Alzheimerjeve bolezni. </p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Znižano kopičenje radiofarmaka v:</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>parietalnem režnju,</td>
                     </tr>
                     <tr>
                        <td>posteriornem temporalnem režnju,</td>
                     </tr>
                     <tr>
                        <td>posteriornem delu girusa cinguli,</td>
                     </tr>
                     <tr>
                        <td>prekuneusu,</td>
                     </tr>
                     <tr>
                        <td>medialnem temporalnem režnju in</td>
                     </tr>
                     <tr>
                        <td>predfrontalni skorji (pri napredovali bolezni).</td>
                     </tr>
                     <tr>
                        <td>Ohranjeno kopičenje radiofarmaka v:</td>
                     </tr>
                     <tr>
                        <td>bazalnih ganglijih,</td>
                     </tr>
                     <tr>
                        <td>talamusu,</td>
                     </tr>
                     <tr>
                        <td>malih možganih,</td>
                     </tr>
                     <tr>
                        <td>primarni senzorno-motorični skorji in</td>
                     </tr>
                     <tr>
                        <td>okcipitalnem režnju.</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <fig position="anchor" id="fig3">
               <label>Slika 3:</label>
               <caption>
                  <p> 
                     <sup>18</sup>F-FDG PET možganov pri (A) zdravem preiskovancu, (B) osebi z Alzheimerjevo boleznijo, (C) demenco z Lewyjevimi telesci in (D) vedenjsko različico frontotemporalne demence (vir: Klinika za nuklearno medicino, UKC Ljubljana).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-03.png"/>
               </p>
            </fig>
            <p>Spremembe se najprej pojavijo v posteriornem delu girusa cinguli (<xref ref-type="bibr" rid="b31">31</xref>). Z napredovanjem se pojavi značilen parieto-temporalni hipometabolizem (<xref ref-type="table" rid="table1">Tabela 1</xref>), pri napredovali bolezni pa pride tudi do upada presnove v predfrontalni skorji. Spremembe so običajno asimetrične in najbolj prizadenejo posteriorne dele neokorteksa.</p>
            <p>S pomočjo <sup>18</sup>F-FDG PET možganov lahko spremljamo potek AB, saj se z napredovanjem bolezni področja znižane presnove razširijo na večji predel neokorteksa, upad pa postaja izrazitejši. Uporaba <sup>18</sup>F-FDG PET možganov nam je poleg zgodnje postavitve diagnoze v pomoč tudi pri razlikovanju med različnimi tipi demenc, katerih klinična slika se, predvsem v začetnih stadijih bolezni, lahko med seboj prekriva (<xref ref-type="bibr" rid="b32">32</xref>).</p>
            <p>Pri bolnikih z blago kognitivno motnjo (BKM) nam <sup>18</sup>F-FDG PET možganov omogoča napoved napredovanja v demenco s približno 90 % občutljivosti in specifičnosti (<xref ref-type="bibr" rid="b33">33</xref>). Pri bolnikih z BKM v sklopu AB opažamo hipometabolizem v področjih, značilnih za AB (<xref ref-type="table" rid="table1">Tabela 1</xref>) (<xref ref-type="bibr" rid="b31">31</xref>).</p>
            <p>Podtipi AB, kot sta posteriorna kortikalna atrofija (PKA) in logopenična različica primarne progresivne afazije (lrPPA), imajo značilno razporeditev presnovnih sprememb. Pri PKA ugotavljamo hipometabolizem okcipitalne skorje, ki v veliki meri sovpada s hipometabolizmom pri DLT (<xref ref-type="bibr" rid="b34">34</xref>). Med obema sindromoma lahko ločimo s slikanjem dopaminskega prenašalca (npr. DaTSCAN), ki je pri AB in PKA ohranjen, pri DLT pa okvarjen (<xref ref-type="bibr" rid="b35">35</xref>,<xref ref-type="bibr" rid="b36">36</xref>). Za lrPPA je značilen hipometabolizem levega temporalnega režnja (zgornji, srednji in spodnji temporalni girus), levega superiornega in inferiornega parietalnega lobusa in prekuneusa (<xref ref-type="bibr" rid="b37">37</xref>). Spremembe presnove pri drugih oblikah primarne progresivne afazije so opisane v poglavju frontotemporalnih demenc.</p>
         </sec>
         <sec id="s2.2" sec-type="Demenca z Lewyjevimi telesci">
            <label>2.2</label>
            <title>Demenca z Lewyjevimi telesci</title>
            <p>DLT je druga najpogostejša nevrodegenerativna demenca pri bolnikih, starejših od 65 let (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b36">36</xref>). Zanjo je značilen nihajoči potek slabšanja kognitivnih sposobnosti, parkinsonizem, vidne halucinacije zgodaj v poteku bolezni, preobčutljivost na nevroleptike in motnje spanja v fazi REM (<xref ref-type="bibr" rid="b36">36</xref>).</p>
            <p>Izrazita prizadetost okcipitalnih režnjev nam pomaga pri razlikovanju od AB z občutljivostjo 83–90 % in specifičnostjo 80–87 % (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b38">38</xref>). Dodatno nam pri razločevanju od AB pomaga tudi sorazmerno ohranjena presnova glukoze v posterornem delu girusa cinguli (znak otočka cinguli, <italic>angl.</italic> cingulate island sign) (<xref ref-type="bibr" rid="b39">39</xref>) ter v medialnem temporalnem režnju (v področju hipokampusa) (<xref ref-type="bibr" rid="b40">40</xref>). Značilna razporeditev presnovnih sprememb, ki jih pri DLT zaznamo z <sup>18</sup>F-FDG PET možganov, je predstavljena v <xref ref-type="table" rid="table2">Tabeli 2</xref> in na <xref ref-type="fig" rid="fig3">Sliki 3</xref>C.</p>
            <table-wrap position="anchor" id="table2">
               <label>Tabela 2:</label>
               <caption>
                  <p> Presnovne značilnosti demence z Lewyjevimi telesci.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Znižano kopičenja radiofarmaka v:</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>primarni vidni skorji,</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>okcipitalni asociacijski skorji in</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>manj izrazito v parietalni in frontalni skorji ter anteriornem delu girusa cinguli.</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <th>Ohranjeno kopičenje radiofarmaka v:</th>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>bazalnih ganglijih,</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>talamusu,</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>malih možganih,</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>primarni senzorno-motorični skorji,</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>medialnih temporalnih režnjih in</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>posteriornem delu girusa cinguli (znak otočka cinguli).</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
         </sec>
         <sec id="s2.3" sec-type="Parkinsonova bolezen z demenco">
            <label>2.3</label>
            <title>Parkinsonova bolezen z demenco</title>
            <p>Bolniki s PB pozno v poteku bolezni pogosto razvijejo demenco; po 20 letih bolezni je ta prisotna pri kar 83 % (<xref ref-type="bibr" rid="b41">41</xref>) bolnikov; govorimo o PB z demenco (PBD).</p>
            <p>Bolniki s PBD imajo znižan privzem <sup>18</sup>F-FDG v različnih predelih možganske skorje. V primerjavi z bolniki s PB brez demence imajo izrazitejši hipometabolizem v parietalni in frontalni skorji možganov (<xref ref-type="bibr" rid="b42">42</xref>).</p>
            <p>Presnovne značilnosti PBD se deloma prekrivajo z DLT. Razlikovanje med PBD in DLT je mogoče predvsem na podlagi hipometabolizma glukoze v okcipitalnem režnju, ki je navadno mnogo izrazitejši pri bolnikih z DLT. Dodatno razlikovanje med DLT in PBD omogoča tudi hipometabolizem lateralne temporalne skorje, ki je pri PBD manj izrazit kot pri DLB. Kljub temu je razlikovanje med obema boleznima s preiskavo <sup>18</sup>F-FDG PET možganov včasih zapleteno in nezanesljivo. Ločimo ju predvsem klinično glede na časovni potek nastopa motnje gibanja in kognitivnega upada. Pri DLT slednji pogosto nastopi že pred motnjo gibanja ali najkasneje eno leto po pričetku gibalnih težav. Klinične in presnovne podobnosti med obema boleznima niso presenetljive, saj gre v obeh primerih za alfasinukleinopatijo s kopičenjem Lewyjevih telesc v možganski skorji.</p>
         </sec>
         <sec id="s2.4" sec-type="Frontotemporalna demenca">
            <label>2.4</label>
            <title>Frontotemporalna demenca</title>
            <p>Pri bolnikih, mlajših od 65 let, je FTD druga najpogostejša oblika demence takoj za AB (<xref ref-type="bibr" rid="b1">1</xref>). Klinično sta zanjo značilna osebnostna spremenjenost in kognitivni upad z motnjo pozornosti, govora in izvršilnih sposobnosti. Glede na klinično sliko delimo FTD na vedenjsko različico (vFTD) in dve obliki primarne progresivne afazije (PPA): nefluentno (nfrPPA) in semantično različico PPA (srPPA).</p>
            <p>Razlikovanje med AD in vFTD (<xref ref-type="fig" rid="fig3">Slika 3</xref>C) s preiskavo <sup>18</sup>F-FDG PET možganov je v večini primerov enostavno. Značilna razporeditev presnovnih sprememb, ki jih zaznamo z <sup>18</sup>F-FDG PET možganov pri treh podtipih FTD, je predstavljena v <xref ref-type="table" rid="table3">Tabeli 3</xref> (<xref ref-type="bibr" rid="b37">37</xref>,<xref ref-type="bibr" rid="b43">43</xref>-<xref ref-type="bibr" rid="b47">47</xref>).</p>
            <table-wrap position="anchor" id="table3">
               <label>Tabela 3:</label>
               <caption>
                  <p> Značilnosti najpogostejših podtipov frontotemporalne demence (FTD) na <sup>18</sup>F-FDG PET možganov. vFTD – vedenjska različica FTD (<xref ref-type="bibr" rid="b44">44</xref>-<xref ref-type="bibr" rid="b46">46</xref>), srPPA – semantična različica primarne progresivne afazije (PPA) (<xref ref-type="bibr" rid="b37">37</xref>,<xref ref-type="bibr" rid="b47">47</xref>), nfrPPA – nefluentna različica PPA (<xref ref-type="bibr" rid="b43">43</xref>).</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>vFTD:</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Znižano kopičenja radiofarmaka v:</td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>frontalnih režnjih (orbitofrontalno, frontopolarno, medialno frontalno, dorzolateralno, lateralno inferiorno frontalno in v anterirornem delu girusa cinguli);</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>temporalnih režnjih in subkortikalnih strukturah sive možganovine (napredovala bolezen).</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <th>srPPA:</th>
                     </tr>
                     <tr>
                        <td>Znižano kopičenja radiofarmaka v:</td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>levem anteriornem temporalnem režnju.</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <th>nfrPPA (relativno heterogena skupina):</th>
                     </tr>
                     <tr>
                        <td>Znižano kopičenja radiofarmaka v:</td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>frontalni skorji levo (spodnja in srednja frontalna, dorzolateralna predfrontalna in frontopolarna skorja, Brocovo področje);</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>temporalni skorji levo (Wernickejevo področje, srednje in inferiorne temporalne regije);</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>v začetnih stadijih bolezni hipometabolizem leve inzule in frontalne operkularne regije.</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td>Ohranjeno kopičenje radiofarmaka v:</td>
                     </tr>
                     <tr>
                        <td>
                           <list>
                              <list-item>
                                 <label>•</label>
                                 <p>hipokampusih in amigdaloidnem jedru.</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
         </sec>
         <sec id="s2.5" sec-type="Vaskularna demenca">
            <label>2.5</label>
            <title>Vaskularna demenca</title>
            <p>Diagnozo vaskularne demence navadno postavimo na podlagi klinične slike ob pristnosti žilnih sprememb na morfoloških slikovnih preiskavah (CT in MRI). V specifičnih okoliščinah je smiselno opraviti <sup>18</sup>F-FDG PET možganov za ugotavljanje hkratne prisotnosti AB ali drugih nevrodegenerativnih bolezni (<xref ref-type="bibr" rid="b30">30</xref>).</p>
            <p>Vzorec kopičenja radiofarmaka je odvisen od velikosti in povirja prizadetega žilja. Če je prizadeta večja možganska arterija, bo izpad metabolizma viden v prizadetem povirju v skladu s spremembami na strukturnih slikah (<xref ref-type="bibr" rid="b48">48</xref>). Pri multiinfarktni prizadetosti subkortikalnih struktur bo vzorec kopičenja <sup>18</sup>F-FDG lahko zelo variabilen in bo navadno koreliral z ishemičnimi spremembami, vidnimi na morfoloških slikovnih preiskavah. V primerjavi z AB je za vaskularno demenco značilen drugačen vzorec z znižanim kopičenjem subkortikalno in v primarni senzorno-motorični skorji, nasprotno pa so manj prizadeta asociacijska področja (<xref ref-type="bibr" rid="b49">49</xref>).</p>
         </sec>
         <sec id="s2.6" sec-type="Sporadična Creutzfeldt-Jakobova bolezen">
            <label>2.6</label>
            <title>Sporadična Creutzfeldt-Jakobova bolezen</title>
            <p>Sporadična Creutzfeldt-Jakobova bolezen (CJB) je redka hitro potekajoča nevrodegenerativna bolezen, ki nastane kot posledica odlaganja patološkega prionskega proteina v možganovini. Klinično se kaže kot hitro potekajoči kognitivni upad, ki z napredovanjem bolezni napreduje do akinetičnega mutizma (<xref ref-type="bibr" rid="b50">50</xref>). <sup>18</sup>F-FDG PET možganov prikaže obsežna področja hipometabolizma možganov, ki je lahko razmeroma asimetričen in najbolj izrazit v frontalnih, parietalnih režnjih (predvsem medialno), v glavi kaudatusa in talamusih. Metabolizem temporalnega režnja in malih možganov je sorazmerno ohranjen (<xref ref-type="bibr" rid="b51">51</xref>).</p>
         </sec>
      </sec>
      <sec id="s3"
           sec-type="Slikovni prikaz kopičenja patoloških proteinov v možganih">
         <label>3</label>
         <title>Slikovni prikaz kopičenja patoloških proteinov v možganih</title>
         <sec id="s3.1"
              sec-type="Amiloidno slikanje možganov pri diagnosticiranju demence">
            <label>3.1</label>
            <title>Amiloidno slikanje možganov pri diagnosticiranju demence</title>
            <p>Osnovne patomorfološke značilnosti AB so znotrajcelične nevrofibrilarne pentlje, sestavljene iz hiperfosforilirane beljakovine tau in amiloidni plaki, ki sestojijo iz amiloida beta (<xref ref-type="bibr" rid="b52">52</xref>). Alzheimerjevo bolezen danes razumemo kot kontinuum patoloških procesov, ki se začno desetletja pred pojavom prvih kliničnih znakov. Kopičenje patoloških proteinov sproži niz procesov, ki z leti privedejo do kognitivnega upada in demence. Znižanje možganske presnove topografsko korelira s kopičenjem proteina tau oziroma nevrodegeneracije, še preden strukturno slikanje razkrije znake atrofije. Kognitivni upad nastopi z zakasnitvijo; od subjektivne kognitivne pritožbe preko BKM do polno razvite demence (<xref ref-type="fig" rid="fig4">Slika 4</xref>) (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b53">53</xref>). Proteinopatijo lahko torej dokažemo pred pojavom kliničnih znakov.</p>
            <fig position="anchor" id="fig4">
               <label>Slika 4:</label>
               <caption>
                  <p> Sosledje patofizioloških procesov pri Alzheimerjevi bolezni (<xref ref-type="bibr" rid="b12">12</xref>). Aβ – amiloid beta, BKM – blaga kognitivna motnja. Prirejeno po Jack, 2010 (<xref ref-type="bibr" rid="b53">53</xref>) in Petersen, 2010 (<xref ref-type="bibr" rid="b54">54</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-04.png"/>
               </p>
            </fig>
            <p>Patološke beljakovine lahko poleg s slikanjem določamo tudi v likvorju; za AB so značilne znižane vrednosti amiloida beta in povišane vrednosti beljakovine tau in fosforilirane beljakovine tau (p-tau) (<xref ref-type="bibr" rid="b55">55</xref>). Občutljivost preiskave za postavitev diagnoze AB je 91–93 %, specifičnost pa 81–84 % (<xref ref-type="bibr" rid="b56">56</xref>). V Sloveniji je preiskava na voljo v terciarnih nevroloških centrih.</p>
            <p>Prednost slikanja z uporabo radiofarmakov, ki se vežejo na amiloid beta in beljakovino, je v neinvazivnosti preiskave. Spremljamo pa lahko tudi prostorsko in časovno razporeditev amiloida beta (<xref ref-type="bibr" rid="b6">6</xref>). Po drugi strani je preiskava v primerjavi z likvorsko diagnostiko dražja. Glavni pomen dokazovanja patološkega substrata za živa je v zgodnji in pravilni diagnozi. Zgodnja diagnoza s pomočjo bioloških označevalcev je tudi predpogoj za izbor preiskovancev v kliničnih študijah AB za spremljanje učinkovitosti specifičnih zdravljenj (<xref ref-type="bibr" rid="b57">57</xref>). Velik klinični pomen pa bodo imele tovrstne preiskave v prihodnosti, ko bo na voljo vzročno zdravljenje in bo morda mogoče osebe z AB zdraviti že v predklinični fazi bolezni (<xref ref-type="bibr" rid="b6">6</xref>).</p>
            <p>Zaradi etičnih dilem, ki jih prinašajo preiskave, ker lahko potrdijo diagnozo hude in neozdravljive bolezni, so bile pripravljene natančne smernice z indikacijami za amiloidne slikovne preiskave (<xref ref-type="bibr" rid="b58">58</xref>,<xref ref-type="bibr" rid="b59">59</xref>). Slikanje je na mestu pri bolnikih z napredujočo BKM, pri bolnikih z atipičnim potekom ter pri bolnikih z demenco, ki so mlajši od 65 let. Preiskava pa ni smiselna pri starejših bolnikih s klasično klinično sliko demence pri AB, za opredelitev stopnje demence, prav tako ne pri zdravih preiskovancih s pozitivno družinsko anamnezo in pri osebah s subjektivno kognitivno pritožbo (<xref ref-type="bibr" rid="b59">59</xref>).</p>
            <p>Prvi in najbolj raziskani specifični amiloidni radiofarmak <sup>11</sup>C-PiB (<xref ref-type="bibr" rid="b19">19</xref>) se pri AB kopiči predvsem v frontalni možganski skorji, v cingulatnem girusu, prekuneusu, striatumu, parietalni in lateralni temporalni možganski skorji. Okcipitalna, somatosenzorna in meziotemporalna skorja kopiči manj radiofarmaka, prav tako tudi skorja malih možganov (<xref ref-type="bibr" rid="b60">60</xref>). Ta vzorec se ujema z rezultati patohistoloških študij razporeditve amiloida beta. Vrednotenje amiloidnega slikanja je ne glede na opisani vzorec razporeditve kopičenja amiloida beta dihotomno: izvid je bodisi pozitiven bodisi negativen (<xref ref-type="fig" rid="fig5">Slika 5</xref>). Za uporabo v klinični praksi so registrirani trije radiofarmaki, označeni z <sup>18</sup>F: <sup>18</sup>F-flutemetamol (Vizamyl), <sup>18</sup>F-florbetaben (NeuraCeq) in <sup>18</sup>F-florbetapir (AMYViD). Pri bolnikih z AB imajo podobno razporeditev kot <sup>11</sup>C-PiB in prav tako dobro ločijo med AB in zdravimi osebami (<xref ref-type="bibr" rid="b60">60</xref>). Radiofarmak florbetapir se klinično najpogosteje uporablja, občutljivost preiskave z njegovo uporabo pa je 92 %, specifičnost pa 90,5–100 % (<xref ref-type="bibr" rid="b61">61</xref>).</p>
            <fig position="anchor" id="fig5">
               <label>Slika 5:</label>
               <caption>
                  <p> Amiloidni PET z <sup>18</sup>F-flutemetamolom (Vizamyl) pri zdravem preiskovancu (A) in pri bolniku z AB (B). Pri zdravem preiskovancu se radiofarmak nespecifično veže v globoki beli možganovini in v nekaterih globokih jedrih, v možganski skorji pa ni kopičenja. Pri bolniku z AB je meja med sivo in belo možganovino zabrisana, kopičenje radiofarmaka je prisotno vse do roba možganske skorje (vir: Klinika za nuklearno medicino, UKC Ljubljana).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-05.png"/>
               </p>
            </fig>
            <p>Tudi pri podtipih AB, kot sta npr. posteriorna kortikalna atrofija (PKA) ali logopenična različica primarne progresivne afazije (lrPPA), amiloidno slikanje prikaže kopičenje amiloida beta. Razporeditev amiloida v možganih je podobna pri vseh podptipi AB.</p>
            <p>Amiloid beta je osnovni patofiziološki dejavnik tudi pri cerebralni amiloidni angiopatiji (CAA), pri kateri se kopiči v mediji in adventiciji leptomeningealnih in kortikalnih arterij in arteriol v centralnem živčevju. Posledica tega procesa je vaskulopatija z ishemičnimi dogodki in možganskimi krvavitvami. Z amiloidnim slikanjem lahko dokažemo kopičenje amiloida beta tudi pri CAA, vzorec kopičenja pa je nekoliko drugačen kot pri AB; več se ga kopiči okcipitalno (<xref ref-type="bibr" rid="b62">62</xref>).</p>
            <p>Amiloidno slikanje je pozitivno tudi pri okoli 50 % bolnikih z DLT (<xref ref-type="bibr" rid="b63">63</xref>). Vzorec kopičenja je pri DLT podoben kot pri AB, intenzivnost pa je nižja (<xref ref-type="bibr" rid="b60">60</xref>). Za DLT je sicer značilno kopičenje α-syn. Pri FTD in CJB z amiloidnimi slikovnimi preiskavami kopičenja amiloida beta ne zaznamo.</p>
         </sec>
         <sec id="s3.2" sec-type="Slikanje proteina tau pri demencah">
            <label>3.2</label>
            <title>Slikanje proteina tau pri demencah</title>
            <p>Poleg amiloidnega slikanja je v zadnjih letih na voljo slikanje tau, za zdaj le v raziskovalne namene. Na voljo je več radiofarmakov, najpogosteje je v uporabi AV1451. Razporeditev tau pri AB in drugih tauopatijah za razliko od amiloida beta dobro korelira s klinično sliko, zato je slikanje tau primerno tudi za spremljanje napredovanja bolezni (<xref ref-type="bibr" rid="b60">60</xref>).</p>
         </sec>
      </sec>
      <sec id="s4"
           sec-type="Vloga nuklearnomedicinskih preiskav pri diagnosticiranju nevrodegenerativnih parkinsonizmov">
         <label>4</label>
         <title>Vloga nuklearnomedicinskih preiskav pri diagnosticiranju nevrodegenerativnih parkinsonizmov</title>
         <p>Parkinsonizem je klinični sindrom bradikineze s pridruženo okorelostjo in/ali tremorjem v mirovanju (<xref ref-type="bibr" rid="b64">64</xref>). Je osrednja klinična značilnost skupine nevrodegenerativnih bolezni, med katerimi je najpogostejša Parkinsonova bolezen (PB). Redkejši so tako imenovani parkinsonizmi plus, pri katerih poleg parkinsonizma klinično ugotovimo dodatne simptome in znake. Mednje uvrščamo multiplo sistemsko atrofijo (MSA), progresivno supranuklearno paralizo (PSP), kortikobazalno degeneracijo (KBD) in demenco z Lewyjevimi telesci (DLT).</p>
         <p>MSA tako kot PB in DLT uvrščamo med alfasinukleinopatije, v nasprotju s PB pa so zanjo značini: slabši odziv na zdravljenje z levodopo, avtonomna in pri nekaterih oblikah cerebelarna prizadetost (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b65">65</xref>). PSP in KBD uvrščamo med tauopatije. Z razliko od PB je za PSP značilen na levodopo slabo odziven parkinsonizem s pridruženo zgodnjo posturalno motnjo oziroma padci, motnjami vertikalnih očesnih gibov in kognitivnim upadom (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b66">66</xref>). KBD od PB ločimo glede na izrazito asimetrično klinično sliko, pri kateri so parkinsonizmu pridruženi distonija, mioklonizmi, orobukalna apraksija in apraksija udov, kortikalni senzibilitetni izpad in sindrom tujega uda (<italic>angl.</italic> alien limb syndrome) (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b67">67</xref>).</p>
         <sec id="s4.1"
              sec-type="Slikovni prikaz integritete dopaminergičnega sistema">
            <label>4.1</label>
            <title>Slikovni prikaz integritete dopaminergičnega sistema</title>
            <p>Diagnozo PB in ostalih parkinsonizmov lahko s precejšnjo natančnostjo postavimo klinično (<xref ref-type="bibr" rid="b64">64</xref>). Včasih pa je klinično težko ločiti med esencialnim ali distoničnim tremorjem in tremorjem pri PB oz. drugih parkinsonizmih ali pa med nevrodegenerativnim in iatrogenim parkinsonizmom (<xref ref-type="bibr" rid="b68">68</xref>,<xref ref-type="bibr" rid="b69">69</xref>). V teh primerih nam lahko ključno pomaga scintigrafija dopaminskega prenašalca z <sup>123</sup>I-ioflupanom (DaTSCAN, <xref ref-type="fig" rid="fig6">Slika 6</xref>). Preiskava je primerna tudi za razlikovanje med AB in DLT (<xref ref-type="bibr" rid="b36">36</xref>,<xref ref-type="bibr" rid="b69">69</xref>), saj gre pri bolnikih z DLT, podobno kot pri drugih nevrodegenerativnih parkinsonizmih, za predsinaptično dopaminergično okvaro. Včasih je smiselna tudi pri diagnosticiranju parkinsonizma, ki dlje časa ne napreduje, ali vaskularnega parkinsonizma, pri katerem je izvid praviloma normalen, razen če gre pri bolniku za vaskularno spremembo v substanci nigri ali nigro-striatalnih povezavah. Pri razlikovanju med esencialnim tremorjem in PB dosega DaTSCAN specifičnost in občutljivost okoli 95 % (<xref ref-type="bibr" rid="b70">70</xref>), pri razlikovanju med DLT in drugimi demencami pa 85 % oz. 95 % (<xref ref-type="bibr" rid="b35">35</xref>).</p>
            <fig position="anchor" id="fig6">
               <label>Slika 6:</label>
               <caption>
                  <p> Scintigrafija dopaminskega prenašalca z <sup>123</sup>I-ioflupanom (DaTSCAN) pri zdravem preiskovancu (A) in bolniku s Parkinsonovo boleznijo (B) (vir: Klinika za nuklearno medicino, UKC Ljubljana).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-06.png"/>
               </p>
            </fig>
            <p>Nekatera zdravila lahko nekoliko vplivajo na izid DaTSCAN (stimulanti centralnega živčevja, nekateri antidepresivi, opioidi, med dopaminergičinim zdravili rotigotin), vendar je ta vpliv sorazmerno majhen, zato jih pred preiskavo večinoma ne ukinjamo (<xref ref-type="bibr" rid="b71">71</xref>).</p>
            <p>Ker je presinaptični dopaminergični sistem okvarjen pri vseh nevrodegenerativnih parkinsonizmih, ta preiskava ni primerna za razlikovanje med njimi. V ta namen moramo proučiti presnovo celotnih možganov z <sup>18</sup>F-FDG PET s poudarkom na ugotavljanju aktivnosti v bazalnih ganglijev.</p>
         </sec>
         <sec id="s4.2" sec-type="18F-FDG PET možganov pri parkinsonizmih">
            <label>4.2</label>
            <title><sup>18</sup>F-FDG PET možganov pri parkinsonizmih</title>
            <p>V nasprotju s parkinsonizmi plus je za PB značilna ohranjena oz. celo povišana presnovna aktivnost v bazalnih ganglijih (predvsem putamnu in globusu pallidusu), kar je posledica motnje na ravni inhibicijskih nevronov, ki projicirajo iz substance nigre (<xref ref-type="bibr" rid="b72">72</xref>) (<xref ref-type="fig" rid="fig7">Slika 7</xref>A). Bolniki s PB imajo globalno znižano presnovo možganske skorje (<xref ref-type="bibr" rid="b73">73</xref>). Z napredovanjem bolezni in kognitivnim upadom se hipometabolizem skorje poglablja, kot je opisano v poglavju PB z demenco.</p>
            <fig position="anchor" id="fig7">
               <label>Slika 7:</label>
               <caption>
                  <p> 
                     <sup>18</sup>F-FDG PET možganov pri (A) Parkinsonovi bolezni, (B) multipli sistemski atrofiji, (C) progresivni supranuklearni paralizi in (D) kortikobazalni degeneraciji (vir: Klinika za nuklearno medicino, UKC Ljubljana).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-07.png"/>
               </p>
            </fig>
            <p>S statistično mrežno analizo (metoda SSM-PCA, opisana prej) so v več neodvisnih kohortah bolnikov s PB identificirali za PB značilen kovariatni presnovni vzorec (<italic>angl</italic>
               <italic>.</italic> Parkinson‘s disease related pattern, PDRP) na <xref ref-type="fig" rid="fig8">Sliki 8</xref>, ki ga zaznamuje izrazit hipometabolizem parieto-okcipitalno in v predmotorični skorji ter z njim povezan hipermetabolizem v področju putamnov, talamusa, možganskega debla, centralnega dela malih možganov in primarnega senzorimotoričnega korteksa (<xref ref-type="bibr" rid="b74">74</xref>,<xref ref-type="bibr" rid="b75">75</xref>).</p>
            <fig position="anchor" id="fig8">
               <label>Slika 8:</label>
               <caption>
                  <p> Presnovni vzorec Parkinsonove bolezni (PDRP), identificiran na vzorcu slovenskih bolnikov (<xref ref-type="bibr" rid="b75">75</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2935-web-resources/image/zdravvestn-2935-sl-08.png"/>
               </p>
            </fig>
            <p>Pri bolnikih z MSA <sup>18</sup>F-FDG PET možganov prikaže znižan metabolizem glukoze v področju striatuma (predvsem v posteriornih delih putamnov), v možganskem deblu in malih možganih (<xref ref-type="bibr" rid="b76">76</xref>). Z <sup>18</sup>F-FDG PET možganov lahko ločimo tudi razlike med podtipoma MSA: parkinsonskim (MSA-P), pri katerem v klinični sliki prevladuje parkinsonizem (izraziteje znižan metabolizem v področju bazalnih ganglijev) in cerebelarnim (MSA-C), pri katerem je v ospredju ataksija (izraziteje znižan metabolizem v področju malih možganov) (<xref ref-type="fig" rid="fig7">Slika 7</xref>B) (<xref ref-type="bibr" rid="b77">77</xref>).</p>
            <p>Za PSP je značilen izrazit hipometabolizem bilateralne medialne frontalne skorje, predmotoričnih in prefrontalnih področij ter striatuma (izraziteje na področju caput nuclei caudati), v talamusu in možganskem deblu (<xref ref-type="fig" rid="fig7">Slika 7</xref>C) (<xref ref-type="bibr" rid="b78">78</xref>).</p>
            <p>Pri KBD <sup>18</sup>F-FDG PET možganov skladno s klinično sliko prikaže izrazito asimetrične spremembe v možganovini z izrazitejšim upadom presnovne aktivnosti na nasprotni strani od bolj prizadete strani. Hipometabolizem je navadno najbolj izrazit v parietalni skorji, prisoten pa je tudi v primarni somatosenzorični skorji, medialnem in lateralnem predmotoričnem področju, striatumu in talamusu (<xref ref-type="fig" rid="fig7">Slika 7</xref>D) (<xref ref-type="bibr" rid="b78">78</xref>).</p>
            <p>Na presnovno aktivnost možganov vplivajo številna zdravila. Klinično so pomembni antipsihotiki (tako klasični kot novejši), saj pomembno povečajo presnovno aktivnost v bazalnih ganglijih (<xref ref-type="bibr" rid="b79">79</xref>). Ob sumu na nevrodegenerativni parkinsonizem je zato v izogib za PB značilnemu lažno pozitivnemu izvidu <sup>18</sup>F-FDG PET možganov potrebno opozoriti, da bolnik prejema antipsihotik. Druga zdravila nimajo večjega vpliva in jih pred preiskavo ne ukinjamo.</p>
            <p>Med parkinsonizmi lahko ločimo na osnovi ocene <sup>18</sup>F-FDG PET možganov, natančnost pa se pomembno zviša z uporabo statističnega algoritma, ki pri vsakem posameznem preiskovancu izračuna izraženost vseh parkinsonskih vzorcev. Na osnovi izraženosti vzorcev algoritem izračuna verjetnost obolelosti za določen parkinsonizem (<xref ref-type="bibr" rid="b28">28</xref>).</p>
         </sec>
      </sec>
      <sec id="s5"
           sec-type="Vloga MRI pri postavitvi diagnoze in vzporednice z metabolnim slikanjem">
         <label>5</label>
         <title>Vloga MRI pri postavitvi diagnoze in vzporednice z metabolnim slikanjem</title>
         <p>V članku smo predstavili možnosti za uporabo funkcijskih nuklearnomedicinskih slikovnih preiskav za izboljšanje zanesljivosti postavljene klinične diagnoze. Navedenih preiskav ne izvajamo rutinsko pri vseh bolnikih, saj niso dostopne v vseh centrih, tudi v terciranih ustanovah jih praviloma uporabljamo, ko se soočimo s klinično dilemo oz. s specifičnim kliničnim vprašanjem. Nasprotno pa strukturno slikanje, kot sta računalniška tomografija (CT) ali magnetno resonančno slikanje (MRI), predstavlja priporočeno presejalno metodo za izključitev morebitnega ozdravljivega vzroka kognitivnega upada (<xref ref-type="bibr" rid="b80">80</xref>). Ocena strukture možganov lahko prispeva k izboljšani natančnosti klinične diagnoze. Če ni kontraindikacij, je MRI metoda izbire zaradi višje ločljivosti in možnosti prikaza raznolikih lastnosti tkiv. Natančna ocena in mnenje specialista nevroradiologa sta v obravnavi nepogrešljiva, sistematični pristop pregledovanja MRI posnetkov pa je v pomoč pri postavitvi diagnoze tudi zdravnikom drugih specialnosti.</p>
         <p>V predlaganem poenostavljenem algoritmu pregledovanja MRI možganov se lahko najprej osredinimo na prisotnost sprememb, ki jih v možganovini ne pričakujemo (<xref ref-type="bibr" rid="b80">80</xref>). Na ta način izključimo prisotnost t. i. kirurškega vzroka kognitivnega upada, ki je lahko ozdravljiv. V to skupino sodijo predvsem znotralobanjski tumorji in subduralni hematom. Tudi povečana količina sicer intrakranialno normalno prisotne strukture, tj. cerebrospinalnega likvorja, ki se kaže s povečanjem možganskih prekatov, lahko nakazuje vzrok za kognitivne motnje. V diferencialni diagnostiki kognitivnih motenj ali parkinsonizmov ob takšnem izvidu strukturnega slikanja in ustrezni klinični sliki največkrat pomislimo na normotenzivni hidrocefalus.</p>
         <p>V naslednjem koraku se osredinimo na spremembo signala, ki je praviloma znotraj bele in sive možganovine enakomeren. Zvišana intenziteta signala bele možganovine na T2 in FLAIR (<italic>angl.</italic> fluid attenuation inversion recovery<italic>) </italic>poudarjenih sekvencah lahko kaže na vaskularno etiologijo kognitivne motnje ali parkinsonizma, dodatno pa lahko k diagnozi prispeva prisotnost drugih znakov bolezni drobnih žil, kot so lakune ali nemi infarkti (<xref ref-type="bibr" rid="b81">81</xref>). Magnetno dovzetno poudarjeno slikanje (<italic>angl.</italic> susceptibility weighted imaging, SWI) je novejše MR-pulzno zaporedje, ki omogoča boljšo kontrastnost zaradi različne magnetne dovzetnosti snovi, kot so železo, kri in razpadni produkti hemoglobina ter kalcij (<xref ref-type="bibr" rid="b82">82</xref>). Spremembe signala na SWI lahko kažejo na prisotnost mikrokrvavitev v sklopu bolezni drobnih žil ali amiloidne angiopatije. Prisotnost železa ali kalcinacij je lahko tudi nespecifičen kazalec nevrodegenerativne patologije pri demencah in različnih motnjah gibanja (<xref ref-type="bibr" rid="b83">83</xref>). Za diagnozo CJB je občutljivo difuzijsko MR slikanje (<italic>angl</italic>
            <italic>.</italic> difussion weighted imaging, DWI), pri katerem najdemo v predelu možganske skorje (t. i. kortikalni trak) in bazalnih ganglijev zvišan signal zaradi omejenega gibanja molekul vode (<xref ref-type="bibr" rid="b50">50</xref>).</p>
         <p>V tretjem koraku ocenimo vzorec atrofije, pri čemer pregledamo 3D-T1 poudarjene sekvence gradientnega odmeva v različnih ravninah. Za AB je najznačilnejša atrofija medialnih temporalnih režnjev, vendar so pri napredovali AB atrofični tudi drugi predeli, vključno s parietalnim in frontalnim režnjem (<xref ref-type="bibr" rid="b84">84</xref>). Pri oblikah FTD, pri katerih izstopa motnja govora, je vzorec atrofije asimetričen – atrofija je izrazitejša v levi hemisferi: temporalno pri srPPA in lrPPA oz. frontalno pri nfrPPA (<xref ref-type="bibr" rid="b85">85</xref>). Pri vFTD se atrofija izrazi predvsem frontalno. Za vse demence pa je značilno, da z napredovanjem bolezni hkrati z javljanjem simptomov prizadetosti novih kognitivnih domen prihaja tudi do širjenja atrofije, zaradi česar je strukturno slikanje v napredovali fazi bolezni manj povedno. Simetrična generalizirana atrofija lahko spremlja recimo AB, DLT in vaskularno demenco, v manjši meri pa je lahko izražena tudi pri zdravem staranju (<xref ref-type="bibr" rid="b80">80</xref>).</p>
         <p>Medtem ko pri bolnikih z idiopatsko PB brez pridružene demence atrofija na MRI ni posebej izrazita, pa lahko specifični vzorci atrofije prispevajo k razlikovanju idiopatske PB od ostalih parkinsonizmov oz. med posameznimi parkinsonizmi plus. Za PSP je značilna atrofija mezencefalona in frontalnega režnja. Pri KBD MR preiskava največkrat razkrije asimetrično atrofijo frontoparietalno, lahko pa je atrofija frontalnega režnja tudi razmeroma simetrična. Za MSA je značilna pontocerebelarna atrofija (<xref ref-type="bibr" rid="b86">86</xref>).</p>
         <p>Med vzorci atrofije na strukturni MR preiskavi in hipometabolizmom na posnetkih <sup>18</sup>F-FDG PET možganov lahko potegnemo precej vzporednic – za atrofična področja je navadno značilna nižja presnovna aktivnost in obratno. Kljub temu pa lahko kombinacija obeh metod pomembno prispeva k zaznavi patoloških sprememb in postavitvi diagnoze (<xref ref-type="bibr" rid="b87">87</xref>). Metabolnemu PET slikanju so komplementarne tudi nekatere novejše MRI metode, ki jih v klinični praksi še ne uporabljamo redno. S funkcijskim MRI v mirovanju lahko prepoznamo t. i. privzeto možgansko omrežje. Sestavljajo ga možganska področja, ki so najbolj aktivna v t. i. »stanju mirovanja« (<xref ref-type="bibr" rid="b88">88</xref>). Za nekatere nevrodegenerativne bolezni, med drugim za AB, je značilna razgradnja tega vzorca (<xref ref-type="bibr" rid="b89">89</xref>). Z merjenjem možganskega pretoka krvi, ki je neposredno odvisen od presnovne aktivnosti možganovine, pa lahko tudi z MRI pridobimo podobne informacije kot z <sup>18</sup>F-FDG PET možganov. Pri tem največkrat uporabljamo različne MRI perfuzijske metode, kot sta T2* in T1 perfuzijska metoda, pri katerih bolniku dovajamo gadolinijevo kontrastno sredstvo (Gd-KS). Podobne rezultate lahko pridobimo z metodo arterijskega označevanja spinov (<italic>angl.</italic> arterial spin labeling), ki ne potrebuje Gd-KS.</p>
      </sec>
      <sec id="s6" sec-type="Zaključek">
         <label>6</label>
         <title>Zaključek</title>
         <p>Slikovni biološki označevalci nevrodegenerativnih bolezni možganov postajajo vse pomembnejše orodje klinika pri zgodnji postavitvi natančne diagnoze kot tudi v raziskavah. Nuklearnomedicinske slikovne preiskave lahko z dokazom možganske patologije na neinvaziven način pomembno izboljšajo natančnost diagnoze nevrodegenerativnih bolezni možganov. Z razvojem radiofarmakov se možnosti prikaza patoloških procesov v možganih stalno širijo.</p>
         <p>Zaradi raznolike in prekrivajoče se klinične slike nevrodegenerativnih proteinopatij diagnozo teh bolezni vse pogosteje postavljamo z biološkimi označevalci. V raziskovalne namene tako diagnoze AB ne postavimo več na podlagi kliničnih meril, temveč z rabo t. i. klasifikacije A/T/N, ki temelji na izvidu nalaganja amiloida -beta (A) in proteina tau (T) v možganovini ter dokaza okvare živčnih celic oziroma nevrodegeneracije (N) (<xref ref-type="bibr" rid="b90">90</xref>). Glede na vse večjo vlogo bioloških označevalcev pričakujemo, da bodo v prihodnosti diagnoze nevrodegenerativnih boleznih temeljile predvsem na teh spoznanjih.</p>
      </sec>
      <sec id="s7" sec-type="Pravopisno pojasnilo">
         <label>7</label>
         <title>Pravopisno pojasnilo</title>
         <p>Inštitut za slovenski jezik Frana Ramovša ZRC SAZU v uradnem stališču svetuje uporabo velike začetnice tudi pri poimenovanjih bolezni vselej, ko je lastno ime, po katerem se neka bolezen imenuje, še v splošni, zlasti strokovni zavesti. To stališče torej odpravlja razlago, da bi bilo treba tovrstna poimenovanja tolmačiti zvrstno, ne lastniško.  Zato so redaktorji pogosto uveljavili pisanje z malo začetnico. Zdravniški vestnik upošteva  novo uradno stališče in uporablja veliko začetnico za npr. Parkinsonovo in Alzheimerjevo bolezen.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Erkkinen</surname>
                     <given-names>MG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kim</surname>
                     <given-names>MO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geschwind</surname>
                     <given-names>MD</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases</article-title>. 
                    <source>Cold Spring Harb Perspect Biol</source>. 
                    <year>2018</year>
                    <month>Apr</month>;
                    <volume>10</volume>(
                    <issue>4</issue>):
                    <fpage>a033118</fpage>. 
                    <pub-id pub-id-type="doi">10.1101/cshperspect.a033118</pub-id>
                    <pub-id pub-id-type="pmid">28716886</pub-id>
                    <issn>1943-0264</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kovacs</surname>
                     <given-names>GG</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine</article-title>. 
                    <source>Int J Mol Sci</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>17</volume>(
                    <issue>2</issue>):
                    <fpage>189</fpage>. 
                    <pub-id pub-id-type="doi">10.3390/ijms17020189</pub-id>
                    <pub-id pub-id-type="pmid">26848654</pub-id>
                    <issn>1661-6596</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jack</surname>
                     <given-names>CR</given-names>
                     <suffix>Jr</suffix>
                  </name>, 
                        <name name-style="western">
                     <surname>Bennett</surname>
                     <given-names>DA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blennow</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carrillo</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dunn</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haeberlein</surname>
                     <given-names>SB</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Contributors</collab>
                    </person-group>. 
                    <article-title>NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease</article-title>. 
                    <source>Alzheimers Dement</source>. 
                    <year>2018</year>
                    <month>Apr</month>;
                    <volume>14</volume>(
                    <issue>4</issue>):
                    <fpage>535</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id>
                    <pub-id pub-id-type="pmid">29653606</pub-id>
                    <issn>1552-5260</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Vanderschaeghe</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schaeverbeke</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bruffaerts</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vandenberghe</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dierickx</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context</article-title>. 
                    <source>Alzheimers Res Ther</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>9</volume>(
                    <issue>1</issue>):
                    <fpage>92</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/s13195-017-0321-3</pub-id>
                    <pub-id pub-id-type="pmid">29197423</pub-id>
                    <issn>1758-9193</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>LeWitt</surname>
                     <given-names>PA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rezai</surname>
                     <given-names>AR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Leehey</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ojemann</surname>
                     <given-names>SG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Flaherty</surname>
                     <given-names>AW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eskandar</surname>
                     <given-names>EN</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2011</year>
                    <month>Apr</month>;
                    <volume>10</volume>(
                    <issue>4</issue>):
                    <fpage>309</fpage>–
                    <lpage>19</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70039-4</pub-id>
                    <pub-id pub-id-type="pmid">21419704</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Villemagne</surname>
                     <given-names>VL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Doré</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bourgeat</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Burnham</surname>
                     <given-names>SC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Laws</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salvado</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Aβ-amyloid and Tau Imaging in Dementia</article-title>. 
                    <source>Semin Nucl Med</source>. 
                    <year>2017</year>
                    <month>Jan</month>;
                    <volume>47</volume>(
                    <issue>1</issue>):
                    <fpage>75</fpage>–
                    <lpage>88</lpage>. 
                    <pub-id pub-id-type="doi">10.1053/j.semnuclmed.2016.09.006</pub-id>
                    <pub-id pub-id-type="pmid">27987560</pub-id>
                    <issn>0001-2998</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lin</surname>
                     <given-names>EC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alavi</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>PET and PET/CT- a clinical guide</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Lin</surname>
                     <given-names>EC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alavi</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>Thieme Medical</source>. 
                    <publisher-loc>New york</publisher-loc>: 
                    <publisher-name>Thieme</publisher-name>; 
                    <year>2009</year>. pp. 
                    <fpage>3</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1055/b-002-74271</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Berti</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pupi</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mosconi</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PET/CT in diagnosis of dementia</article-title>. 
                    <source>Ann N Y Acad Sci</source>. 
                    <year>2011</year>
                    <month>Jun</month>;
                    <volume>1228</volume>(
                    <issue>1</issue>):
                    <fpage>81</fpage>–
                    <lpage>92</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06015.x</pub-id>
                    <pub-id pub-id-type="pmid">21718326</pub-id>
                    <issn>0077-8923</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Berti</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pupi</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mosconi</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PET/CT in diagnosis of movement disorders</article-title>. 
                    <source>Ann N Y Acad Sci</source>. 
                    <year>2011</year>
                    <month>Jun</month>;
                    <volume>1228</volume>(
                    <issue>1</issue>):
                    <fpage>93</fpage>–
                    <lpage>108</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06025.x</pub-id>
                    <pub-id pub-id-type="pmid">21718327</pub-id>
                    <issn>0077-8923</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brown</surname>
                     <given-names>RK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bohnen</surname>
                     <given-names>NI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>KK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Minoshima</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frey</surname>
                     <given-names>KA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Brain PET in suspected dementia: patterns of altered FDG metabolism</article-title>. 
                    <source>Radiographics</source>. 
                    <year>2014</year>
                    <month>May-Jun</month>;
                    <volume>34</volume>(
                    <issue>3</issue>):
                    <fpage>684</fpage>–
                    <lpage>701</lpage>. 
                    <pub-id pub-id-type="doi">10.1148/rg.343135065</pub-id>
                    <pub-id pub-id-type="pmid">24819789</pub-id>
                    <issn>0271-5333</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Herholz</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Guidance for reading FDG PET scans in dementia patients</article-title>. 
                    <source>Q J Nucl Med Mol Imaging</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>58</volume>(
                    <issue>4</issue>):
                    <fpage>332</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">25391316</pub-id>
                    <issn>1824-4785</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jack</surname>
                     <given-names>CR</given-names>
                     <suffix>Jr</suffix>
                  </name>, 
                        <name name-style="western">
                     <surname>Knopman</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jagust</surname>
                     <given-names>WJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Petersen</surname>
                     <given-names>RC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weiner</surname>
                     <given-names>MW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aisen</surname>
                     <given-names>PS</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2013</year>
                    <month>Feb</month>;
                    <volume>12</volume>(
                    <issue>2</issue>):
                    <fpage>207</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(12)70291-0</pub-id>
                    <pub-id pub-id-type="pmid">23332364</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Varrone</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Asenbaum</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vander Borght</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Booij</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nobili</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Någren</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>European Association of Nuclear Medicine Neuroimaging Committee</collab>
                    </person-group>. 
                    <article-title>EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2</article-title>. 
                    <source>Eur J Nucl Med Mol Imaging</source>. 
                    <year>2009</year>
                    <month>Dec</month>;
                    <volume>36</volume>(
                    <issue>12</issue>):
                    <fpage>2103</fpage>–
                    <lpage>10</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00259-009-1264-0</pub-id>
                    <pub-id pub-id-type="pmid">19838705</pub-id>
                    <issn>1619-7070</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Antonini</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>DeNotaris</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PET and SPECT functional imaging in Parkinson’s disease</article-title>. 
                    <source>Sleep Med</source>. 
                    <year>2004</year>
                    <month>Mar</month>;
                    <volume>5</volume>(
                    <issue>2</issue>):
                    <fpage>201</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.sleep.2003.10.013</pub-id>
                    <pub-id pub-id-type="pmid">15033144</pub-id>
                    <issn>1389-9457</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Stoessl</surname>
                     <given-names>AJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Martin</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McKeown</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sossi</surname>
                     <given-names>V</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Advances in imaging in Parkinson’s disease</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2011</year>
                    <month>Nov</month>;
                    <volume>10</volume>(
                    <issue>11</issue>):
                    <fpage>987</fpage>–
                    <lpage>1001</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70214-9</pub-id>
                    <pub-id pub-id-type="pmid">22014434</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wenning</surname>
                     <given-names>GK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Donnemiller</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Granata</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Riccabona</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Poewe</surname>
                     <given-names>W</given-names>
                  </name>
                    </person-group>. 
                    <article-title>
                        <sup>123</sup>I-β-CIT and 
                        <sup>123</sup>I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease
                    </article-title>. 
                    <source>Mov Disord</source>. 
                    <year>1998</year>
                    <month>May</month>;
                    <volume>13</volume>(
                    <issue>3</issue>):
                    <fpage>438</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/mds.870130311</pub-id>
                    <pub-id pub-id-type="pmid">9613734</pub-id>
                    <issn>0885-3185</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hellwig</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Amtage</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kreft</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buchert</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Winz</surname>
                     <given-names>OH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vach</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism</article-title>. 
                    <source>Neurology</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>79</volume>(
                    <issue>13</issue>):
                    <fpage>1314</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.0b013e31826c1b0a</pub-id>
                    <pub-id pub-id-type="pmid">22914831</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Villemagne</surname>
                     <given-names>VL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fodero-Tavoletti</surname>
                     <given-names>MT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Masters</surname>
                     <given-names>CL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rowe</surname>
                     <given-names>CC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Tau imaging: early progress and future directions</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>14</volume>(
                    <issue>1</issue>):
                    <fpage>114</fpage>–
                    <lpage>24</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70252-2</pub-id>
                    <pub-id pub-id-type="pmid">25496902</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Klunk</surname>
                     <given-names>WE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Engler</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nordberg</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blomqvist</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Holt</surname>
                     <given-names>DP</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B</article-title>. 
                    <source>Ann Neurol</source>. 
                    <year>2004</year>
                    <month>Mar</month>;
                    <volume>55</volume>(
                    <issue>3</issue>):
                    <fpage>306</fpage>–
                    <lpage>19</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ana.20009</pub-id>
                    <pub-id pub-id-type="pmid">14991808</pub-id>
                    <issn>0364-5134</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Clark</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schneider</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bedell</surname>
                     <given-names>BJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Beach</surname>
                     <given-names>TG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bilker</surname>
                     <given-names>WB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mintun</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>AV45-A07 Study Group</collab>
                    </person-group>. 
                    <article-title>Use of florbetapir-PET for imaging β-amyloid pathology</article-title>. 
                    <source>JAMA</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>305</volume>(
                    <issue>3</issue>):
                    <fpage>275</fpage>–
                    <lpage>83</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jama.2010.2008</pub-id>
                    <pub-id pub-id-type="pmid">21245183</pub-id>
                    <issn>0098-7484</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sabri</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sabbagh</surname>
                     <given-names>MN</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Seibyl</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barthel</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Akatsu</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ouchi</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Florbetaben Phase 3 Study Group</collab>
                    </person-group>. 
                    <article-title>Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study</article-title>. 
                    <source>Alzheimers Dement</source>. 
                    <year>2015</year>
                    <month>Aug</month>;
                    <volume>11</volume>(
                    <issue>8</issue>):
                    <fpage>964</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jalz.2015.02.004</pub-id>
                    <pub-id pub-id-type="pmid">25824567</pub-id>
                    <issn>1552-5260</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wolk</surname>
                     <given-names>DA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grachev</surname>
                     <given-names>ID</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buckley</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kazi</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grady</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trojanowski</surname>
                     <given-names>JQ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology</article-title>. 
                    <source>Arch Neurol</source>. 
                    <year>2011</year>
                    <month>Nov</month>;
                    <volume>68</volume>(
                    <issue>11</issue>):
                    <fpage>1398</fpage>–
                    <lpage>403</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/archneurol.2011.153</pub-id>
                    <pub-id pub-id-type="pmid">21747004</pub-id>
                    <issn>0003-9942</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mathis</surname>
                     <given-names>CA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopresti</surname>
                     <given-names>BJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ikonomovic</surname>
                     <given-names>MD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Klunk</surname>
                     <given-names>WE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Small-molecule PET Tracers for Imaging Proteinopathies</article-title>. 
                    <source>Semin Nucl Med</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>47</volume>(
                    <issue>5</issue>):
                    <fpage>553</fpage>–
                    <lpage>75</lpage>. 
                    <pub-id pub-id-type="doi">10.1053/j.semnuclmed.2017.06.003</pub-id>
                    <pub-id pub-id-type="pmid">28826526</pub-id>
                    <issn>0001-2998</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bagchi</surname>
                     <given-names>DP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yu</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perlmutter</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xu</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mach</surname>
                     <given-names>RH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tu</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent</article-title>. 
                    <source>Plos One</source>. 
                    <year>2013</year>;
                    <volume>8</volume>(
                    <issue>2</issue>):
                    <fpage>e55031</fpage>.
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0055031</pub-id>
                    <pub-id pub-id-type="pmid">23405108</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="book">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Friston</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ashburner</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kiebel</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nichols</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Penny</surname>
                     <given-names>WD</given-names>
                  </name>
                    </person-group>. 
                    <source>Statistical parametric mapping: the analysis of funtional brain images</source>. 
                    <publisher-loc>Cambridge</publisher-loc>:
                    <publisher-name>Academic Press</publisher-name>; 
                    <year>2007</year>. 
                    <pub-id pub-id-type="doi">10.1016/B978-012372560-8/50002-4</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Minoshima</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frey</surname>
                     <given-names>KA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koeppe</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Foster</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuhl</surname>
                     <given-names>DE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>1995</year>
                    <month>Jul</month>;
                    <volume>36</volume>(
                    <issue>7</issue>):
                    <fpage>1238</fpage>–
                    <lpage>48</lpage>.
                    <pub-id pub-id-type="pmid">7790950</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Spetsieris</surname>
                     <given-names>PG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ma</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dhawan</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eidelberg</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features</article-title>. 
                    <source>Neuroimage</source>. 
                    <year>2009</year>
                    <month>May</month>;
                    <volume>45</volume>(
                    <issue>4</issue>):
                    <fpage>1241</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.12.063</pub-id>
                    <pub-id pub-id-type="pmid">19349238</pub-id>
                    <issn>1053-8119</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <label>28. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Tang</surname>
                     <given-names>CC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Poston</surname>
                     <given-names>KL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eckert</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Feigin</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frucht</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gudesblatt</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2010</year>
                    <month>Feb</month>;
                    <volume>9</volume>(
                    <issue>2</issue>):
                    <fpage>149</fpage>–
                    <lpage>58</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70002-8</pub-id>
                    <pub-id pub-id-type="pmid">20061183</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b29">
            <label>29. </label>
            <mixed-citation publication-type="webpage">
                    <person-group>
                  <name name-style="western">
                     <surname/>
                  </name>
               </person-group>.
                    <source>Strategija obvladovanja demence v Sloveniji do leta 2020</source>. 
                    <comment>Available from:<uri>https://www.gov.si/assets/ministrstva/MZ/DOKUMENTI/Preventiva-in-skrb-za-zdravje/nenalezljive-bolezni/Strategija_obvladovanja_demence.pdf</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b30">
            <label>30. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ishii</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PET approaches for diagnosis of dementia</article-title>. 
                    <source>AJNR Am J Neuroradiol</source>. 
                    <year>2014</year>
                    <month>Nov-Dec</month>;
                    <volume>35</volume>(
                    <issue>11</issue>):
                    <fpage>2030</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.3174/ajnr.A3695</pub-id>
                    <pub-id pub-id-type="pmid">23945233</pub-id>
                    <issn>0195-6108</issn>
                </mixed-citation>
         </ref>
         <ref id="b31">
            <label>31. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Minoshima</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Giordani</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berent</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frey</surname>
                     <given-names>KA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Foster</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuhl</surname>
                     <given-names>DE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease</article-title>. 
                    <source>Ann Neurol</source>. 
                    <year>1997</year>
                    <month>Jul</month>;
                    <volume>42</volume>(
                    <issue>1</issue>):
                    <fpage>85</fpage>–
                    <lpage>94</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ana.410420114</pub-id>
                    <pub-id pub-id-type="pmid">9225689</pub-id>
                    <issn>0364-5134</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <label>32. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mosconi</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tsui</surname>
                     <given-names>WH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Herholz</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pupi</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drzezga</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lucignani</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2008</year>
                    <month>Mar</month>;
                    <volume>49</volume>(
                    <issue>3</issue>):
                    <fpage>390</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.107.045385</pub-id>
                    <pub-id pub-id-type="pmid">18287270</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b33">
            <label>33. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Drzezga</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grimmer</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Riemenschneider</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lautenschlager</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Siebner</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alexopoulus</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2005</year>
                    <month>Oct</month>;
                    <volume>46</volume>(
                    <issue>10</issue>):
                    <fpage>1625</fpage>–
                    <lpage>32</lpage>.
                    <pub-id pub-id-type="pmid">16204712</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b34">
            <label>34. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Whitwell</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Graff-Radford</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Singh</surname>
                     <given-names>TD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drubach</surname>
                     <given-names>DA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Senjem</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spychalla</surname>
                     <given-names>AJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>
                        <sup>18</sup>F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies
                    </article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>58</volume>(
                    <issue>4</issue>):
                    <fpage>632</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.116.179903</pub-id>
                    <pub-id pub-id-type="pmid">27688479</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b35">
            <label>35. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Papathanasiou</surname>
                     <given-names>ND</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boutsiadis</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dickson</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bomanji</surname>
                     <given-names>JB</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Diagnostic accuracy of ¹²³I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies</article-title>. 
                    <source>Parkinsonism Relat Disord</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>18</volume>(
                    <issue>3</issue>):
                    <fpage>225</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.parkreldis.2011.09.015</pub-id>
                    <pub-id pub-id-type="pmid">21975260</pub-id>
                    <issn>1353-8020</issn>
                </mixed-citation>
         </ref>
         <ref id="b36">
            <label>36. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>McKeith</surname>
                     <given-names>IG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boeve</surname>
                     <given-names>BF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dickson</surname>
                     <given-names>DW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Halliday</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Taylor</surname>
                     <given-names>JP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weintraub</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium</article-title>. 
                    <source>Neurology</source>. 
                    <year>2017</year>
                    <month>Jul</month>;
                    <volume>89</volume>(
                    <issue>1</issue>):
                    <fpage>88</fpage>–
                    <lpage>100</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.0000000000004058</pub-id>
                    <pub-id pub-id-type="pmid">28592453</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b37">
            <label>37. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cerami</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dodich</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Greco</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Iannaccone</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Magnani</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Marcone</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia</article-title>. 
                    <source>J Alzheimers Dis</source>. 
                    <year>2017</year>;
                    <volume>55</volume>(
                    <issue>1</issue>):
                    <fpage>183</fpage>–
                    <lpage>97</lpage>. 
                    <pub-id pub-id-type="doi">10.3233/JAD-160682</pub-id>
                    <pub-id pub-id-type="pmid">27662315</pub-id>
                    <issn>1387-2877</issn>
                </mixed-citation>
         </ref>
         <ref id="b38">
            <label>38. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ishii</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soma</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kono</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sofue</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miyamoto</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yoshikawa</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2007</year>
                    <month>May</month>;
                    <volume>48</volume>(
                    <issue>5</issue>):
                    <fpage>704</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.106.035691</pub-id>
                    <pub-id pub-id-type="pmid">17475957</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b39">
            <label>39. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lim</surname>
                     <given-names>SM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Katsifis</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Villemagne</surname>
                     <given-names>VL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Best</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jones</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Saling</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>50</volume>(
                    <issue>10</issue>):
                    <fpage>1638</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.109.065870</pub-id>
                    <pub-id pub-id-type="pmid">19759102</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b40">
            <label>40. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ishii</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soma</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kono</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sofue</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miyamoto</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yoshikawa</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2007</year>
                    <month>May</month>;
                    <volume>48</volume>(
                    <issue>5</issue>):
                    <fpage>704</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.106.035691</pub-id>
                    <pub-id pub-id-type="pmid">17475957</pub-id>
                    <issn>0161-5505</issn>                    
                </mixed-citation>
         </ref>
         <ref id="b41">
            <label>41. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hely</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reid</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adena</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Halliday</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morris</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008 Apr 30;23(6):837- 844</article-title>. 
                    <source>Mov Disord</source>. 
                    <year>2008</year>
                    <month>Feb</month>;
                    <volume>23</volume>(
                    <issue>6</issue>):
                    <fpage>837</fpage>–
                    <lpage>44</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/mds.21956</pub-id>
                    <pub-id pub-id-type="pmid">18307261</pub-id>
                    <issn>0885-3185</issn>
                </mixed-citation>
         </ref>
         <ref id="b42">
            <label>42. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Yong</surname>
                     <given-names>SW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yoon</surname>
                     <given-names>JK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>An</surname>
                     <given-names>YS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>PH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies</article-title>. 
                    <source>Eur J Neurol</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>14</volume>(
                    <issue>12</issue>):
                    <fpage>1357</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1468-1331.2007.01977.x</pub-id>
                    <pub-id pub-id-type="pmid">17941855</pub-id>
                    <issn>1351-5101</issn>
                </mixed-citation>
         </ref>
         <ref id="b43">
            <label>43. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Perneczky</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Diehl-Schmid</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pohl</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drzezga</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kurz</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Non-fluent progressive aphasia: cerebral metabolic patterns and brain reserve</article-title>. 
                    <source>Brain Res</source>. 
                    <year>2007</year>
                    <month>Feb</month>;
                    <volume>1133</volume>(
                    <issue>1</issue>):
                    <fpage>178</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.brainres.2006.11.054</pub-id>
                    <pub-id pub-id-type="pmid">17184752</pub-id>
                    <issn>0006-8993</issn>
                </mixed-citation>
         </ref>
         <ref id="b44">
            <label>44. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Salmon</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Garraux</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Delbeuck</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Collette</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kalbe</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zuendorf</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia</article-title>. 
                    <source>Neuroimage</source>. 
                    <year>2003</year>
                    <month>Sep</month>;
                    <volume>20</volume>(
                    <issue>1</issue>):
                    <fpage>435</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1053-8119(03)00346-X</pub-id>
                    <pub-id pub-id-type="pmid">14527604</pub-id>
                    <issn>1053-8119</issn>
                </mixed-citation>
         </ref>
         <ref id="b45">
            <label>45. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Foster</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Heidebrink</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Clark</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jagust</surname>
                     <given-names>WJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arnold</surname>
                     <given-names>SE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barbas</surname>
                     <given-names>NR</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease</article-title>. 
                    <source>Brain</source>. 
                    <year>2007</year>
                    <month>Oct</month>;
                    <volume>130</volume>(
                    <issue>Pt 10</issue>):
                    <fpage>2616</fpage>–
                    <lpage>35</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/brain/awm177</pub-id>
                    <pub-id pub-id-type="pmid">17704526</pub-id>
                    <issn>0006-8950</issn>
                </mixed-citation>
         </ref>
         <ref id="b46">
            <label>46. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Diehl-Schmid</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grimmer</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drzezga</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bornschein</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Riemenschneider</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Förstl</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study</article-title>. 
                    <source>Neurobiol Aging</source>. 
                    <year>2007</year>
                    <month>Jan</month>;
                    <volume>28</volume>(
                    <issue>1</issue>):
                    <fpage>42</fpage>–
                    <lpage>50</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.11.002</pub-id>
                    <pub-id pub-id-type="pmid">16448722</pub-id>
                    <issn>0197-4580</issn>
                </mixed-citation>
         </ref>
         <ref id="b47">
            <label>47. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Desgranges</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matuszewski</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Piolino</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chételat</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mézenge</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Landeau</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Anatomical and functional alterations in semantic dementia: a voxel-based MRI and PET study</article-title>. 
                    <source>Neurobiol Aging</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>28</volume>(
                    <issue>12</issue>):
                    <fpage>1904</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.08.006</pub-id>
                    <pub-id pub-id-type="pmid">16979268</pub-id>
                    <issn>0197-4580</issn>
                </mixed-citation>
         </ref>
         <ref id="b48">
            <label>48. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kerrouche</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Herholz</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mielke</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Holthoff</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baron</surname>
                     <given-names>JC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>
                        <sup>18</sup>FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis
                    </article-title>. 
                    <source>J Cereb Blood Flow Metab</source>. 
                    <year>2006</year>
                    <month>Sep</month>;
                    <volume>26</volume>(
                    <issue>9</issue>):
                    <fpage>1213</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600296</pub-id>
                    <pub-id pub-id-type="pmid">16525414</pub-id>
                    <issn>0271-678X</issn>
                </mixed-citation>
         </ref>
         <ref id="b49">
            <label>49. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Heiss</surname>
                     <given-names>WD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zimmermann-Meinzingen</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PET imaging in the differential diagnosis of vascular dementia</article-title>. 
                    <source>J Neurol Sci</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>322</volume>(
                    <issue>1-2</issue>):
                    <fpage>268</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jns.2012.09.023</pub-id>
                    <pub-id pub-id-type="pmid">23043907</pub-id>
                    <issn>0022-510X</issn>
                </mixed-citation>
         </ref>
         <ref id="b50">
            <label>50. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zerr</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kallenberg</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Summers</surname>
                     <given-names>DM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Romero</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Taratuto</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Heinemann</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease</article-title>. 
                    <source>Brain</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>132</volume>(
                    <issue>Pt 10</issue>):
                    <fpage>2659</fpage>–
                    <lpage>68</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/brain/awp191</pub-id>
                    <pub-id pub-id-type="pmid">19773352</pub-id>
                    <issn>0006-8950</issn>
                </mixed-citation>
         </ref>
         <ref id="b51">
            <label>51. </label>
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rus</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Popović</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grmek</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ibrulj</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zupančič Križnar</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Granda</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <chapter-title>Metabolic Biomarkers of Sporadic Creutzfeldt-Jakob Disease</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Gregorič Kramberger</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <role>ed</role>
                    </person-group>.
                    <source>8th Cognitive Day: Dementias and the Role of Fluid Biomarkers</source>.
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Center for Cognitive Imparements, Department of Neurology, Neurology Clinic, University Medical Centre Ljubljana</publisher-name>;
                    <year>2019</year>.
                </mixed-citation>
         </ref>
         <ref id="b52">
            <label>52. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Masters</surname>
                     <given-names>CL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bateman</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blennow</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rowe</surname>
                     <given-names>CC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sperling</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cummings</surname>
                     <given-names>JL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Alzheimer’s disease</article-title>. 
                    <source>Nat Rev Dis Primers</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>15056</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/nrdp.2015.56</pub-id>
                    <pub-id pub-id-type="pmid">27188934</pub-id>
                    <issn>2056-676X</issn>
                </mixed-citation>
         </ref>
         <ref id="b53">
            <label>53. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jack</surname>
                     <given-names>CR</given-names>
                     <suffix>Jr</suffix>
                  </name>, 
                        <name name-style="western">
                     <surname>Wiste</surname>
                     <given-names>HJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vemuri</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weigand</surname>
                     <given-names>SD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Senjem</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zeng</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Alzheimer’s Disease Neuroimaging Initiative</collab>
                    </person-group>. 
                    <article-title>Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease</article-title>. 
                    <source>Brain</source>. 
                    <year>2010</year>
                    <month>Nov</month>;
                    <volume>133</volume>(
                    <issue>11</issue>):
                    <fpage>3336</fpage>–
                    <lpage>48</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/brain/awq277</pub-id>
                    <pub-id pub-id-type="pmid">20935035</pub-id>
                    <issn>0006-8950</issn>
                </mixed-citation>
         </ref>
         <ref id="b54">
            <label>54. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Petersen</surname>
                     <given-names>RC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Alzheimer’s disease: progress in prediction</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2010</year>
                    <month>Jan</month>;
                    <volume>9</volume>(
                    <issue>1</issue>):
                    <fpage>4</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70330-8</pub-id>
                    <pub-id pub-id-type="pmid">20083022</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b55">
            <label>55. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Skillbäck</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Farahmand</surname>
                     <given-names>BY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rosén</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mattsson</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nägga</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kilander</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cerebrospinal fluid tau and amyloid-β
                        <sub>1-42</sub> in patients with dementia
                    </article-title>. 
                    <source>Brain</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>138</volume>(
                    <issue>Pt 9</issue>):
                    <fpage>2716</fpage>–
                    <lpage>31</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/brain/awv181</pub-id>
                    <pub-id pub-id-type="pmid">26133663</pub-id>
                    <issn>0006-8950</issn>
                </mixed-citation>
         </ref>
         <ref id="b56">
            <label>56. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Duits</surname>
                     <given-names>FH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teunissen</surname>
                     <given-names>CE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bouwman</surname>
                     <given-names>FH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Visser</surname>
                     <given-names>PJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mattsson</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zetterberg</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?</article-title>
                    <source>Alzheimers Dement</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>10</volume>(
                    <issue>6</issue>):
                    <fpage>713</fpage>–
                    <lpage>723.e2</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jalz.2013.12.023</pub-id>
                    <pub-id pub-id-type="pmid">24721526</pub-id>
                    <issn>1552-5260</issn>
                </mixed-citation>
         </ref>
         <ref id="b57">
            <label>57. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sevigny</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chiao</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bussière</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weinreb</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Williams</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maier</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease</article-title>. 
                    <source>Nature</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>537</volume>(
                    <issue>7618</issue>):
                    <fpage>50</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nature19323</pub-id>
                    <pub-id pub-id-type="pmid">27582220</pub-id>
                    <issn>0028-0836</issn>
                </mixed-citation>
         </ref>
         <ref id="b58">
            <label>58. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Johnson</surname>
                     <given-names>KA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Minoshima</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bohnen</surname>
                     <given-names>NI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Donohoe</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Foster</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Herscovitch</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Alzheimer’s Association</collab>; 
                        <collab>Society of Nuclear Medicine and Molecular Imaging</collab>; 
                        <collab>Amyloid Imaging Taskforce</collab>
                    </person-group>. 
                    <article-title>Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association</article-title>. 
                    <source>Alzheimers Dement</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>9</volume>(
                    <issue>1</issue>):
                    <fpage>e-1</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jalz.2013.01.002</pub-id>
                    <pub-id pub-id-type="pmid">23360977</pub-id>
                    <issn>1552-5260</issn>
                </mixed-citation>
         </ref>
         <ref id="b59">
            <label>59. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Minoshima</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drzezga</surname>
                     <given-names>AE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barthel</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bohnen</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Djekidel</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lewis</surname>
                     <given-names>DH</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0</article-title>. 
                    <source>J Nucl Med</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>57</volume>(
                    <issue>8</issue>):
                    <fpage>1316</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.2967/jnumed.116.174615</pub-id>
                    <pub-id pub-id-type="pmid">27481605</pub-id>
                    <issn>0161-5505</issn>
                </mixed-citation>
         </ref>
         <ref id="b60">
            <label>60. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Villemagne</surname>
                     <given-names>VL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Amyloid imaging: Past, present and future perspectives</article-title>. 
                    <source>Ageing Res Rev</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>30</volume>:
                    <fpage>95</fpage>–
                    <lpage>106</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.arr.2016.01.005</pub-id>
                    <pub-id pub-id-type="pmid">26827784</pub-id>
                    <issn>1568-1637</issn>
                </mixed-citation>
         </ref>
         <ref id="b61">
            <label>61. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Clark</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pontecorvo</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Beach</surname>
                     <given-names>TG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bedell</surname>
                     <given-names>BJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Coleman</surname>
                     <given-names>RE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Doraiswamy</surname>
                     <given-names>PM</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>AV-45-A16 Study Group</collab>
                    </person-group>. 
                    <article-title>Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study</article-title>. 
                    <source>Lancet Neurol</source>. 
                    <year>2012</year>
                    <month>Aug</month>;
                    <volume>11</volume>(
                    <issue>8</issue>):
                    <fpage>669</fpage>–
                    <lpage>78</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1474-4422(12)70142-4</pub-id>
                    <pub-id pub-id-type="pmid">22749065</pub-id>
                    <issn>1474-4422</issn>
                </mixed-citation>
         </ref>
         <ref id="b62">
            <label>62. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Charidimou</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Farid</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tsai</surname>
                     <given-names>HH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tsai</surname>
                     <given-names>LK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yen</surname>
                     <given-names>RF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baron</surname>
                     <given-names>JC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance</article-title>. 
                    <source>J Neurol Neurosurg Psychiatry</source>. 
                    <year>2018</year>
                    <month>Apr</month>;
                    <volume>89</volume>(
                    <issue>4</issue>):
                    <fpage>410</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/jnnp-2017-316851</pub-id>
                    <pub-id pub-id-type="pmid">29070646</pub-id>
                    <issn>0022-3050</issn>
                </mixed-citation>
         </ref>
         <ref id="b63">
            <label>63. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kantarci</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lowe</surname>
                     <given-names>VJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boeve</surname>
                     <given-names>BF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Senjem</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tosakulwong</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lesnick</surname>
                     <given-names>TG</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies</article-title>. 
                    <source>Ann Neurol</source>. 
                    <year>2017</year>
                    <month>Jan</month>;
                    <volume>81</volume>(
                    <issue>1</issue>):
                    <fpage>58</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ana.24825</pub-id>
                    <pub-id pub-id-type="pmid">27863444</pub-id>
                    <issn>0364-5134</issn>
                </mixed-citation>
         </ref>
         <ref id="b64">
            <label>64. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Postuma</surname>
                     <given-names>RB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berg</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stern</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Poewe</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Olanow</surname>
                     <given-names>CW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oertel</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>MDS clinical diagnostic criteria for Parkinson’s disease</article-title>. 
                    <source>Mov Disord</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>30</volume>(
                    <issue>12</issue>):
                    <fpage>1591</fpage>–
                    <lpage>601</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/mds.26424</pub-id>
                    <pub-id pub-id-type="pmid">26474316</pub-id>
                    <issn>0885-3185</issn>
                </mixed-citation>
         </ref>
         <ref id="b65">
            <label>65. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gilman</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wenning</surname>
                     <given-names>GK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Low</surname>
                     <given-names>PA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Brooks</surname>
                     <given-names>DJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mathias</surname>
                     <given-names>CJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trojanowski</surname>
                     <given-names>JQ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Second consensus statement on the diagnosis of multiple system atrophy</article-title>. 
                    <source>Neurology</source>. 
                    <year>2008</year>
                    <month>Aug</month>;
                    <volume>71</volume>(
                    <issue>9</issue>):
                    <fpage>670</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/01.wnl.0000324625.00404.15</pub-id>
                    <pub-id pub-id-type="pmid">18725592</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b66">
            <label>66. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Litvan</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Agid</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Calne</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Campbell</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dubois</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Duvoisin</surname>
                     <given-names>RC</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop</article-title>. 
                    <source>Neurology</source>. 
                    <year>1996</year>
                    <month>Jul</month>;
                    <volume>47</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.47.1.1</pub-id>
                    <pub-id pub-id-type="pmid">8710059</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b67">
            <label>67. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Armstrong</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Litvan</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lang</surname>
                     <given-names>AE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bak</surname>
                     <given-names>TH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bhatia</surname>
                     <given-names>KP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Borroni</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Criteria for the diagnosis of corticobasal degeneration</article-title>. 
                    <source>Neurology</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>80</volume>(
                    <issue>5</issue>):
                    <fpage>496</fpage>–
                    <lpage>503</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.0b013e31827f0fd1</pub-id>
                    <pub-id pub-id-type="pmid">23359374</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b68">
            <label>68. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Isaacson</surname>
                     <given-names>SH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fisher</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gupta</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hermanowicz</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kremens</surname>
                     <given-names>DE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lew</surname>
                     <given-names>MF</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective</article-title>. 
                    <source>Expert Rev Neurother</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>17</volume>(
                    <issue>3</issue>):
                    <fpage>219</fpage>–
                    <lpage>25</lpage>. 
                    <pub-id pub-id-type="doi">10.1080/14737175.2017.1256205</pub-id>
                    <pub-id pub-id-type="pmid">27813429</pub-id>
                    <issn>1473-7175</issn>
                </mixed-citation>
         </ref>
         <ref id="b69">
            <label>69. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Flisar</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Puklavec</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grmek</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trošt</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Slikanje SPECT dopaminskega prenašalca pri boleznih možganov</article-title>. 
                    <source>Zdr Vestn</source>. 
                    <year>2008</year>
                    <month>Sep</month>;
                    <volume>77</volume>:
                    <fpage>635</fpage>–
                    <lpage>40</lpage>.
                    <issn>1318-0347</issn>
                </mixed-citation>
         </ref>
         <ref id="b70">
            <label>70. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hauser</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grosset</surname>
                     <given-names>DG</given-names>
                  </name>
                    </person-group>. 
                    <article-title>[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes</article-title>. 
                    <source>J Neuroimaging</source>. 
                    <year>2012</year>
                    <month>Jul</month>;
                    <volume>22</volume>(
                    <issue>3</issue>):
                    <fpage>225</fpage>–
                    <lpage>30</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1552-6569.2011.00583.x</pub-id>
                    <pub-id pub-id-type="pmid">21410815</pub-id>
                    <issn>1051-2284</issn>
                </mixed-citation>
         </ref>
         <ref id="b71">
            <label>71. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Darcourt</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Booij</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tatsch</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Varrone</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vander Borght</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kapucu</surname>
                     <given-names>ÖL</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2</article-title>. 
                    <source>Eur J Nucl Med Mol Imaging</source>. 
                    <year>2010</year>
                    <month>Feb</month>;
                    <volume>37</volume>(
                    <issue>2</issue>):
                    <fpage>443</fpage>–
                    <lpage>50</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00259-009-1267-x</pub-id>
                    <pub-id pub-id-type="pmid">19838702</pub-id>
                    <issn>1619-7070</issn>
                </mixed-citation>
         </ref>
         <ref id="b72">
            <label>72. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brooks</surname>
                     <given-names>DJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pavese</surname>
                     <given-names>N</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Imaging biomarkers in Parkinson’s disease</article-title>. 
                    <source>Prog Neurobiol</source>. 
                    <year>2011</year>
                    <month>Dec</month>;
                    <volume>95</volume>(
                    <issue>4</issue>):
                    <fpage>614</fpage>–
                    <lpage>28</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.08.009</pub-id>
                    <pub-id pub-id-type="pmid">21896306</pub-id>
                    <issn>0301-0082</issn>
                </mixed-citation>
         </ref>
         <ref id="b73">
            <label>73. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Borghammer</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chakravarty</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jonsdottir</surname>
                     <given-names>KY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sato</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matsuda</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ito</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages</article-title>. 
                    <source>Brain Struct Funct</source>. 
                    <year>2010</year>
                    <month>May</month>;
                    <volume>214</volume>(
                    <issue>4</issue>):
                    <fpage>303</fpage>–
                    <lpage>17</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00429-010-0246-0</pub-id>
                    <pub-id pub-id-type="pmid">20361208</pub-id>
                    <issn>1863-2653</issn>
                </mixed-citation>
         </ref>
         <ref id="b74">
            <label>74. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ma</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tang</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spetsieris</surname>
                     <given-names>PG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dhawan</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eidelberg</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility</article-title>. 
                    <source>J Cereb Blood Flow Metab</source>. 
                    <year>2007</year>
                    <month>Mar</month>;
                    <volume>27</volume>(
                    <issue>3</issue>):
                    <fpage>597</fpage>–
                    <lpage>605</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600358</pub-id>
                    <pub-id pub-id-type="pmid">16804550</pub-id>
                    <issn>0271-678X</issn>
                </mixed-citation>
         </ref>
         <ref id="b75">
            <label>75. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Tomše</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jensterle</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grmek</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zaletel</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pirtošek</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dhawan</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Abnormal metabolic brain network associated with Parkinson’s disease: replication on a new European sample</article-title>. 
                    <source>Neuroradiology</source>. 
                    <year>2017</year>
                    <month>May</month>;
                    <volume>59</volume>(
                    <issue>5</issue>):
                    <fpage>507</fpage>–
                    <lpage>15</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00234-017-1821-3</pub-id>
                    <pub-id pub-id-type="pmid">28386687</pub-id>
                    <issn>0028-3940</issn>
                </mixed-citation>
         </ref>
         <ref id="b76">
            <label>76. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Taniwaki</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nakagawa</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yamada</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yoshida</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ohyagi</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sasaki</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cerebral metabolic changes in early multiple system atrophy: a PET study</article-title>. 
                    <source>J Neurol Sci</source>. 
                    <year>2002</year>
                    <month>Aug</month>;
                    <volume>200</volume>(
                    <issue>1-2</issue>):
                    <fpage>79</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0022-510X(02)00151-X</pub-id>
                    <pub-id pub-id-type="pmid">12127681</pub-id>
                    <issn>0022-510X</issn>
                </mixed-citation>
         </ref>
         <ref id="b77">
            <label>77. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Eckert</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barnes</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dhawan</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frucht</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gordon</surname>
                     <given-names>MF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Feigin</surname>
                     <given-names>AS</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>FDG PET in the differential diagnosis of parkinsonian disorders</article-title>. 
                    <source>Neuroimage</source>. 
                    <year>2005</year>
                    <month>Jul</month>;
                    <volume>26</volume>(
                    <issue>3</issue>):
                    <fpage>912</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.neuroimage.2005.03.012</pub-id>
                    <pub-id pub-id-type="pmid">15955501</pub-id>
                    <issn>1053-8119</issn>
                </mixed-citation>
         </ref>
         <ref id="b78">
            <label>78. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Niccolini</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Politis</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism</article-title>. 
                    <source>Eur J Nucl Med Mol Imaging</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>43</volume>(
                    <issue>12</issue>):
                    <fpage>2244</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00259-016-3464-8</pub-id>
                    <pub-id pub-id-type="pmid">27470326</pub-id>
                    <issn>1619-7070</issn>
                </mixed-citation>
         </ref>
         <ref id="b79">
            <label>79. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Berti</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mosconi</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pupi</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging</article-title>. 
                    <source>PET Clin</source>. 
                    <year>2014</year>
                    <month>Apr</month>;
                    <volume>9</volume>(
                    <issue>2</issue>):
                    <fpage>129</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.cpet.2013.10.006</pub-id>
                    <pub-id pub-id-type="pmid">24772054</pub-id>
                    <issn>1556-8598</issn>
                </mixed-citation>
         </ref>
         <ref id="b80">
            <label>80. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Harper</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barkhof</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Scheltens</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schott</surname>
                     <given-names>JM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fox</surname>
                     <given-names>NC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>An algorithmic approach to structural imaging in dementia</article-title>. 
                    <source>J Neurol Neurosurg Psychiatry</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>85</volume>(
                    <issue>6</issue>):
                    <fpage>692</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/jnnp-2013-306285</pub-id>
                    <pub-id pub-id-type="pmid">24133287</pub-id>
                    <issn>0022-3050</issn>
                </mixed-citation>
         </ref>
         <ref id="b81">
            <label>81. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Heiss</surname>
                     <given-names>WD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rosenberg</surname>
                     <given-names>GA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Thiel</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berlot</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>de Reuck</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Neuroimaging in vascular cognitive impairment: a state-of-the-art review</article-title>. 
                    <source>BMC Med</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>14</volume>(
                    <issue>1</issue>):
                    <fpage>174</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/s12916-016-0725-0</pub-id>
                    <pub-id pub-id-type="pmid">27806705</pub-id>
                    <issn>1741-7015</issn>
                </mixed-citation>
         </ref>
         <ref id="b82">
            <label>82. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buch</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Choi</surname>
                     <given-names>HS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Habib</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Susceptibility-weighted imaging: current status and future directions</article-title>. 
                    <source>NMR Biomed</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>30</volume>(
                    <issue>4</issue>):
                    <fpage>e3552</fpage>. 
                    <pub-id pub-id-type="doi">10.1002/nbm.3552</pub-id>
                    <pub-id pub-id-type="pmid">27192086</pub-id>
                    <issn>0952-3480</issn>
                </mixed-citation>
         </ref>
         <ref id="b83">
            <label>83. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Schneider</surname>
                     <given-names>SA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hardy</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bhatia</surname>
                     <given-names>KP</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations</article-title>. 
                    <source>Mov Disord</source>. 
                    <year>2012</year>
                    <month>Jan</month>;
                    <volume>27</volume>(
                    <issue>1</issue>):
                    <fpage>42</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/mds.23971</pub-id>
                    <pub-id pub-id-type="pmid">22031173</pub-id>
                    <issn>0885-3185</issn>
                </mixed-citation>
         </ref>
         <ref id="b84">
            <label>84. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wahlund</surname>
                     <given-names>LO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Julin</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Johansson</surname>
                     <given-names>SE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Scheltens</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study</article-title>. 
                    <source>J Neurol Neurosurg Psychiatry</source>. 
                    <year>2000</year>
                    <month>Nov</month>;
                    <volume>69</volume>(
                    <issue>5</issue>):
                    <fpage>630</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/jnnp.69.5.630</pub-id>
                    <pub-id pub-id-type="pmid">11032615</pub-id>
                    <issn>0022-3050</issn>
                </mixed-citation>
         </ref>
         <ref id="b85">
            <label>85. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gorno-Tempini</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hillis</surname>
                     <given-names>AE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weintraub</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kertesz</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mendez</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cappa</surname>
                     <given-names>SF</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Classification of primary progressive aphasia and its variants</article-title>. 
                    <source>Neurology</source>. 
                    <year>2011</year>
                    <month>Mar</month>;
                    <volume>76</volume>(
                    <issue>11</issue>):
                    <fpage>1006</fpage>–
                    <lpage>14</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.0b013e31821103e6</pub-id>
                    <pub-id pub-id-type="pmid">21325651</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
         <ref id="b86">
            <label>86. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Massey</surname>
                     <given-names>LA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Micallef</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Paviour</surname>
                     <given-names>DC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>O’Sullivan</surname>
                     <given-names>SS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ling</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Williams</surname>
                     <given-names>DR</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy</article-title>. 
                    <source>Mov Disord</source>. 
                    <year>2012</year>
                    <month>Dec</month>;
                    <volume>27</volume>(
                    <issue>14</issue>):
                    <fpage>1754</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/mds.24968</pub-id>
                    <pub-id pub-id-type="pmid">22488922</pub-id>
                    <issn>0885-3185</issn>
                </mixed-citation>
         </ref>
         <ref id="b87">
            <label>87. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dukart</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mueller</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Horstmann</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barthel</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Möller</surname>
                     <given-names>HE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Villringer</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2011</year>
                    <month>Mar</month>;
                    <volume>6</volume>(
                    <issue>3</issue>):
                    <fpage>e18111</fpage>.
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0018111</pub-id>
                    <pub-id pub-id-type="pmid">21448435</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
         </ref>
         <ref id="b88">
            <label>88. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fox</surname>
                     <given-names>MD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Snyder</surname>
                     <given-names>AZ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vincent</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Corbetta</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Van Essen</surname>
                     <given-names>DC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Raichle</surname>
                     <given-names>ME</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The human brain is intrinsically organized into dynamic, anticorrelated functional networks</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2005</year>
                    <month>Jul</month>;
                    <volume>102</volume>(
                    <issue>27</issue>):
                    <fpage>9673</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.0504136102</pub-id>
                    <pub-id pub-id-type="pmid">15976020</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b89">
            <label>89. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Seeley</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crawford</surname>
                     <given-names>RK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhou</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miller</surname>
                     <given-names>BL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Greicius</surname>
                     <given-names>MD</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Neurodegenerative diseases target large-scale human brain networks</article-title>. 
                    <source>Neuron</source>. 
                    <year>2009</year>
                    <month>Apr</month>;
                    <volume>62</volume>(
                    <issue>1</issue>):
                    <fpage>42</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.024</pub-id>
                    <pub-id pub-id-type="pmid">19376066</pub-id>
                    <issn>0896-6273</issn>
                </mixed-citation>
         </ref>
         <ref id="b90">
            <label>90. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jack</surname>
                     <given-names>CR</given-names>
                     <suffix>Jr</suffix>
                  </name>, 
                        <name name-style="western">
                     <surname>Bennett</surname>
                     <given-names>DA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blennow</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carrillo</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Feldman</surname>
                     <given-names>HH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Frisoni</surname>
                     <given-names>GB</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers</article-title>. 
                    <source>Neurology</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>87</volume>(
                    <issue>5</issue>):
                    <fpage>539</fpage>–
                    <lpage>47</lpage>. 
                    <pub-id pub-id-type="doi">10.1212/WNL.0000000000002923</pub-id>
                    <pub-id pub-id-type="pmid">27371494</pub-id>
                    <issn>0028-3878</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
